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Abstract 
Luteinizing hormone-releasing hormone (p-EHWSYGLRPG, LHRH) is a decapeptide 
produced by the hypothalamus that stimulates the secretion of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) from the pituitary gland. This neuropeptide plays a crucial role 
in the regulation of the pituitary/gonadal axis in both males and females. LHRH analogues have 
extensive therapeutic applications in the treatment of hormone-dependent diseases such as breast 
and prostate cancers. Chronic administration of LHRH agonists desensitizes the pituitary gland and 
subsequently suppresses the production of gonadal sex steroids. In addition, LHRH analogues could 
exert direct growth inhibitory effects on cancer cells which are meditated through the LHRH 
receptors expressed on the cell’s membrane. All marketed analogues of LHRH are administered 
parenterally. Given the advantages of the oral administration route such as convenience and patient 
compliance, developing a practical oral delivery system for LHRH would be more useful and 
efficient than existing routes of administration. However, the poor bioavailability and rapid 
enzymatic degradation of the LHRH impede the development of a potent oral pharmaceutical.  
 
The main aim of this research was to develop a carbohydrate-based system for oral delivery of 
LHRH peptide. This research focused mostly on improving the pharmacokinetic profile of LHRH 
and enhancing its oral bioavailability using a glycosylation strategy. Conjugation of peptides with 
carbohydrate moieties has been shown to be a promising strategy in increasing the metabolic 
stability and changing the physicochemical properties of peptides. A library of LHRH analogue 
modified by the attachment of different sugar units (glucose, galactose and lactose) to the N-
terminus, C-terminus or the middle of the peptide sequence was designed and synthesized. Caco-2 
cell monolayers were used as a standard model to evaluate the apparent permeability (Papp) of the 
newly designed analogues across the cell membranes. A significant improvement was observed in 
the Papp of all N-terminally glycosylated LHRH derivatives except for the compound-bearing 
galactose. The greatest Papp value was obtained for the compound bearing a glucose (GS) unit in the 
middle of the sequence ([GS
4
][w
6
]LHRH), and lactose (Lac) at the N-terminus (Lac-
[Q
1
][w
6
]LHRH) with Papp = 58.54×10
-7
 cm/s and 38.42×10
-7
 cm/s, respectively. The contribution of 
intestinal active transport systems including the sodium ion-dependent transporter 1 (SGLT1) and a 
sodium ion-independent facilitative transporter 2 (GLUT2) in the transport of glycosylated LHRH 
derivatives was also elucidated using the Caco-2 cell monolayer model.  
 
The anti-proliferative activity of the peptide derivatives was also examined in different LHRH 
receptor-positive prostate cancer cell lines (LNCaP, DU145 and PC3) in this study. The treatment 
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of LNCaP and DU145 cells with glycosylated LHRH derivatives reduced the cell growth 
significantly (up to 60% decreases in cell viability) after 72 h incubation at 100 µM and 200 µM 
concentrations. The growth of PC3 cells reduced 20% to 30% after 96 h treatment with glycosylated 
LHRH analogues (at 100 µM and 200 µM) showing the less inhibitory effect of the glycosylated 
compounds on PC3 cell growth.  
 
The in vitro metabolic stability of the glycosylated LHRH derivatives was assessed in human 
plasma, Caco-2 cell and rat kidney and liver homogenates. The plasma half-life of the compounds 
increased significantly compared to the parent peptide. Lac-[Q1][w6]LHRH and [GS4][w6]LHRH 
were the most stable derivatives in all these biological matrices. A significant improvement was 
shown in the metabolic stability of the Lac-[Q1]LHRH analogue in the liver homogenates compared 
to LHRH (t1/2 of 47 = min vs. 5 min for LHRH).  
 
To evaluate the in vitro efficacy of glycosylated LHRH derivatives, the stimulatory effect of 
the analogues on LH release was assessed in cultured rat pituitary cells. The secretion of LH was 
significantly increased following the treatment of the cells with Lac-[Q1][w6]LHRH at 5 nM and 10 
nM concentrations. The in vivo efficacy study of Lac-[Q1][w6]LHRH revealed the stimulatory 
activity of the compound in male rats. A marked increase was observed in the release of LH after 
oral administration of 20 µg/kg of the lactose-modified derivative (nAUC=11.33± 1.65 ng/24 h) 
compared to the negative control group (nAUC=4.45± 1.028 ng/24 h). 
 
The oral bioavailability and other pharmacokinetic parameters of Lac-[Q1][w6]LHRH were 
evaluated in male Sprague Dawley rats following intravenous (2.5 mg/kg) and oral (10 mg/kg) 
administrations. The absolute oral bioavailability (F%) of the peptide was found to be 14%, which 
is a remarkable improvement over the poor bioavailability of unmodified peptides (reported to be 
less than 1%). Maximum serum concentration (Cmax= 0.11 µg/mL) was reached after 2 h (Tmax) 
following oral administration of the compound at 10 mg/kg with a half-life of 2.6 h.  
 
In conclusion, we improved the pharmacological properties of LHRH peptide through a 
glycosylation strategy. The attachment of lactose moiety to LHRH had a significant influence on 
the efficacy and pharmacokinetic parameters of the peptide both in vitro and in vivo. These findings 
suggest that Lac-[Q1][w6]LHRH is a promising candidate for the development of an orally active 
peptide with enhanced oral bioavailability. 
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Chapter 1:    Introduction 
 
 
1
1.1 LHRH and its biology 
Luteinizing hormone-releasing hormone (LHRH), also known as gonadotropin-releasing 
hormone (GnRH), plays a crucial role in the control of the reproductive system. LHRH was first 
isolated and synthesized by Schally et al. in 1971 (1). The prohormone contains 92 amino acids in 
its sequence which is produced by the neurosecretory cells of the hypothalamus. Endopeptidases 
process the precursor peptide and convert it to the active form. The active decapeptide is released 
from the hypothalamus in a pulsatile manner and exerts its function by binding to its receptor on the 
anterior pituitary gland where it stimulates the secretion of the gonadotropin hormones, luteinizing 
hormone (LH) and follicle stimulating hormone (FSH). Subsequently, the production of LH and 
FSH controls the function of testes and ovaries, by stimulating the secretion of sex steroids 
including testosterone in males, and oestrogens and progesterone in females (2). Generally, sex 
steroids regulate the hypothalamic–pituitary–gonadal axis through a negative feedback loop (Fig. 
1.1). When the level of sex steroids reaches a threshold, it reduces the secretion of LHRH via two 
ways, either by direct suppression of the LHRH receptor in pituitary cells or by blocking the LH 
secretion and gonadotropin expression (3). 
The amino acid sequence of LHRH is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (Fig. 
1.2). To date, more than 23 isoforms of this hormone have been identified in both mammals and 
non-mammalian vertebrates. There are highly-conserved amino acids in both the N-terminus and 
the C-terminus of the LHRH peptide in all vertebrates indicating that these residues are critically 
important for receptor-binding and hormone activity (4).  
In addition to their regulatory function in the neuroendocrine system, LHRH peptides act as 
neurotransmitters and neuromodulators in the central nervous system or have autocrine/paracrine 
roles in several peripheral tissues (5). The autocrine activity of LHRH is mediated through the 
locally expressed LHRH receptors on the peripheral tissues and may have diverse functions 
including the facilitation of steroidogenesis, cell proliferation, apoptosis, fertilization, and cell 
migration (6). It has also been demonstrated that LHRH plays an important role in regulating 
tumour growth including ovarian and prostate cancers via an autocrine/paracrine function (6, 7).  
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Figure 1.1. The hypothalamic–pituitary–gonadal axis. Pulsatile secretion of LHRH controls the 
synthesis of FSH and LH in the pituitary gland. The production of LH and FSH in turn, regulates 
the secretion of sex hormones from the testes and ovaries that act as feedback hormones in the 
regulation of LHRH secretion. 
 
 
 
Figure 1.2. Molecular structure of natural LHRH. The N-terminus of the peptide contains pyroglutamic 
acid (pGlu) and the C-terminus is amidated. 
 
 
L
3
LHRH receptors (LHRHRs) belong to the family of rhodopsin-like G-coupled protein receptors 
(GPCR) located on the surface of the pituitary gonadotrope cells. The amino acid sequence of the 
LHRH receptor was first identified in 1992 by cDNA clones from rat and human pituitaries (8). 
LHRHR protein contains an extracellular N-terminal region and seven α-helical transmembrane 
(7TM) domains with specific sites for ligand binding (4, 9). There are also three hydrophobic loops 
in both extracellular and cytoplasmic sides which connect 7TM domains to each other. 
Furthermore, the intracellular loops have specific domains for coupling to Gq/11 mediator protein, 
which is involved in the activation of the intracellular signalling pathway (9, 10). Unlike the other 
GPCRs, the intracellular region of LHRHR does not contain a C-terminal tail required for the 
internalisation of the receptor complex. This region is important for desensitisation of the receptor 
(10, 11). The receptor has to be stimulated continuously in order to be desensitized and down-
regulated, which is the mechanism of LHRH agonists on the cognate receptor (12).  
Identification of individual amino acid residues involved in receptor-binding and receptor 
activation of LHRH is critical for designing biologically active LHRH analogues. Studies have 
shown that His
2
 and Trp
3
 play essential roles in the biological activity of the hormone and any 
modification in these positions can decrease the activity of the peptide. Gly
6
 in the middle of the 
sequence facilitates the folding of the peptide. Substitution of position six with a D-amino acid 
generates potent agonist derivatives of LHRH. This modification has been shown to enhance the 
binding affinity to the receptor due to a change in folding conformation. In addition, D-amino acid 
substitution at position six improves the metabolic stability of the modified analogue. The N-
terminal residues in the peptide contribute to the receptor activation predominantly. Replacement of 
the first three N-terminal amino acids with D-amino acids leads to the development of analogues 
with antagonist activity (Fig.1.3) (13, 14). 
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Figure 1.3. Schematic structure of LHRH in folded conformation in which it is bound to its receptor. 
The amino-terminal residues (green) are associated with receptor activation and receptor-binding. Gly 
residue at position six is responsible for a specific folding conformation and it is required for high-affinity 
interaction with mammalian receptors. The last three amino acids at the carboxy-terminus (red) are necessary 
for specificity and high-affinity binding to the LHRH receptor. 
 
1.2 Enzymatic degradation of LHRH  
Native LHRH has a short half-life of 2-5 min in human plasma (15). It has been shown that the 
degradation of LHRH in the brain and peripheral tissues is caused mainly by two enzymes: 1) prolyl 
endopeptidase (PE) and 2) zinc metalloendopeptidase EC 3.4.24.15 (EP24.15). LHRH is initially 
cleaved by PE resulting in the production of nonapeptide (LHRH-(1-9)). The produced nonapeptide 
is a suitable substrate for EP24.15. In the second step, EP24.15 cleaves the peptide bond of LHRH-
(1-9) at position five and six (Tyr
5
-Gly
6
) and forms LHRH-(1-5) (Fig. 1.4). The resulting 
pentapeptide (pGlu
1
-His
2
-Trp
3
-Ser
4
-Tyr
5
) is biologically active and functionally distinct from the 
parent peptide, since it can regulate the gene expression of LHRH and may also stimulate cell 
proliferation in peripheral tissues. A high level of these hydrolysing enzymes has been found in the 
tissues regulating the production of LHRH, such as testes (6). 
It is also believed that pyroglutamyl peptidase (also known as pyrolidone carboxyl peptidase) 
which eliminates pGlu residue from peptides, hydrolyses LHRH at position one (16, 17). Moreover, 
this enzyme has been detected in mammalian serum that might account for plasma degradation of 
the hormone (18). 
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Figure 1.4. Cleavage sites within the LHRH peptide. Prolyl endopeptidase (PE) and EP24.15 are 
involved in the hydrolysis of LHRH. First, PE cleaves the peptide at the ninth position and the resulting 
nonapeptide is cleaved by EP24.15. The hydrolysis products of the latter enzyme are LHRH-(1-5) and 
LHRH-(6-9), of which LHRH-(1-5) is biologically active (6). 
 
1.3 LHRH analogues and their clinical applications 
Elucidation of the LHRH structure and its pivotal role in the reproductive system prompted the 
development of several LHRH agonists and antagonists. These analogues are widely used for the 
treatment of hormone-dependent malignancies including breast, ovary, prostate and endometrial 
cancers, as well as endocrine disorders such as precocious puberty and infertility (19, 20). LHRH 
analogues have been found to be effective for the treatment of Alzheimer disease to decrease the 
level of gonadotropins elevated in patients with dementia (21-23).  
The ultimate effect of both agonists and antagonists of LHRH is to suppress the production of 
sex steroids in males and females via different mechanisms. In agonist therapy, the continuous 
administration of LHRH agonists results in an initial rise in the levels of LH and FSH hormones 
(so-called “flare effect”) followed by the down-regulation of LHRH receptors and the consequent 
decrease of sex steroids (24). For the treatment of prostate cancer in androgen deprivation therapy, 
using LHRH agonists has several advantages including good efficacy with a low level of adverse 
effects and psychological issues compared to the conventional therapies (surgical castration) (25). 
6
This is because the medical castration achieved by LHRH agonists is reversible and therefore makes 
it preferable as a first-line of therapy (26). 
To date, a number of different LHRH analogues (both agonists and antagonists) have been 
synthesized by substitution of amino acids in the middle of the peptide sequence at position six, and 
also by the alteration of the N-terminus and C-terminus of the peptide. These modifications can 
protect the hormone against enzymatic degradation and improve their potency (19, 27).  
[D-Trp
6
]LHRH (triptorelin) is one of the agonists in the market with a higher biological activity 
than the native peptide due to the presence of D-Trp at position six which enhances the enzymatic 
stability of the peptide and its potency. The introduction of a hydrophobic group in the side chain of 
the amino acid residues in the peptide’s sequence can also reduce the sensitivity to proteases and 
protects it from digestion (28). [D-Leu
6
, Pro
9
-NHEt] LHRH (leuprolide), [D-Ser(But)
6
, Pro
9
-
NHEt]LHRH (buserelin) and [D-Ser (But)
6
, Aza-Gly
10
]LHRH (goserelin) are other currently 
available LHRH agonists in the market with improved metabolic stability compared to the parent 
peptide (27, 29).  
 
1.4 Antiproliferative activity of LHRH and its analogues 
It has been shown that LHRH analogues not only suppress the pituitary-gonadal axis but also 
exert a direct growth-inhibitory effect on the tumour growth (30). In addition to pituitary 
expression, LHRH and its receptor are slightly expressed in the peripheral tissues but overexpressed 
in numerous tumours such as prostate and breast cancers (31, 32). It has been shown that LHRH 
receptors in malignant tumours mediate the anti-tumour activity of the LHRH derivatives (33, 34). 
A number of studies demonstrated the different impact of LHRH agonists on the growth rate of the 
cancer cells, e.g. prostate cancer cell lines (35-37).  It has been suggested that LHRH agonists could 
exert a biphasic impact on the cell growth; they inhibit cell proliferation at high concentrations 
whereas they stimulate the growth at low concentrations in cultured cancer cells (38, 39). Medium-
to-high-affinity binding sites were reported for LHRH agonists in LHRH-receptor positive prostate 
cancer cell lines including LNCaP, DU145 and PC3 cells (40). These analogues exert their growth 
inhibitory effect in a time- and dose-dependent manner (41). Studies showed that the growth 
inhibitory effect of LHRH analogues in PC3 is lower than the other cancer cell lines, which could 
be due to the lower rate of LHRH receptors expressed in PC3 cells (30).  
The inhibitory mechanism of LHRH analogues is through a different signalling transduction 
pathway from that in the pituitary cells (42, 43). The antiproliferative activity of LHRH analogues 
is mediated through the plasminogen activator system by reducing the activity of the enzyme in 
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prostate cancer cells which subsequently decreases the migration and invasiveness of cancer cells 
(43). 
 
1.5 Strategies to develop orally active peptide 
All LHRH analogues are administered through parenteral routes including subcutaneous (SC), 
intramuscular (IM) and  intravenous (IV) (44). Due to the advantages of oral administration 
including convenience, high patient compliance and avoidance of infection risk caused by injection, 
the development of an orally active LHRH analogue is highly desirable. LHRH peptide has a poor 
oral bioavailability because of its relatively high molecular weight (limits the absorption through 
intestinal cells) and sensitivity to proteolytic enzymes that prevent its uptake by gastrointestinal 
cells (45). In order to improve the bioavailability of peptides, it is necessary to increase their 
intestinal absorption and protect them from enzymatic degradation. Chemical modifications of the 
peptide’s sequence using glycosylation and lipidation are known to be effective strategies to 
facilitate the oral peptide delivery. Various lipoamino acid (LAA) conjugates of LHRH have been 
synthesized by our group and the enhanced in vitro and in vivo stability and pharmacokinetic 
profiles of the lipidated analogues have been illustrated(46-48). The half-lives of LAA-conjugated 
peptides were increased significantly in Caco-2 cell homogenate in comparison with the parent 
peptide(46). The in vivo intestinal uptake of the lipid-modified LHRH analogues was also improved 
after oral administration (48).  
Conjugation of carbohydrate units to the peptide drugs is a useful strategy to improve their 
pharmacological properties including the bioavailability and stability. Carbohydrate moieties can 
alter the physiochemical properties of peptides and improve their enzymatic stability while retaining 
the biological activity. In addition, the attachment of sugar units to peptides facilitates the transport 
across the biological cell membranes via carrier-mediated transport systems and subsequently 
increases the intestinal absorption of the sugar-conjugated peptides (49, 50). The favourable impact 
of glycosylation on the membrane permeability, metabolic stability and the biological activity of 
glycosylated peptides has been shown in a number of studies (51-55). For instance, the 
glycosylation of somatostatin resulted in a ten-fold increase in the oral bioavailability of the peptide 
without changing its bioactivity to inhibit the release of growth hormone (54). 
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1.6 Research aim and hypothesis 
1.6.1 Hypothesis 
We hypothesized that conjugation of carbohydrate moieties to LHRH enhances the stability 
of the complex as well as increasing the uptake through biological membranes. 
1.6.2 Overall aim  
The main objective of this project was to enhance the oral bioavailability of LHRH 
analogues and develop an orally active peptide. To achieve this goal, we applied a glycosylation 
strategy to improve the metabolic stability of the LHRH peptide and enhance its intestinal 
absorption. This could consequently lead to improved pharmacokinetic properties and increased 
oral bioavailability of LHRH analogues, while maintaining their efficacy. 
   1.6.3 Specific aims: 
Aim 1: Design and synthesis of a small library of LHRH analogues comprised of peptides 
conjugated with carbohydrate moieties and compounds modified by both carbohydrate moieties and 
amino acid substitution. 
Aim 2: Biological evaluation of all synthesized LHRH analogues in vitro including to: 
 examine their enzymatic degradation in Caco-2 cell homogenate to evaluate the 
stability of peptide drug in vitro  
 investigate the apparent permeability of all peptide derivatives in Caco-2 cell 
monolayers 
 measure the half-lives of glycosylated derivatives in human plasma, rat liver and 
kidney membrane homogenates 
 investigate the role of transporters on the vectorial transport of glycosylated LHRH 
 evaluate the in vitro  efficacy of the analogues on release of luteinizing hormone (LH) 
and follicle stimulating hormone (FSH) from cultured pituitary cells. 
Aim 3: Perform an in vivo test for the lead compound (lactose-[Q
1
][w
6
]LHRH) in order to: 
 measure the change in the level of LH in rat plasma following oral administration of the 
compound  
 determine the oral bioavailability of lactose-[Q1][w6]LHRH in Sprague Dawley rats by 
measuring the plasma concentration of the compound after oral and IV administration 
and evaluating the pharmacokinetic (PK) parameters of the compound in rat serum 
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1.7 Thesis organization 
In addition to Chapter 1, there are five more chapters included in this thesis. Chapter 2-5 are 
presented in the form of published or prepared manuscripts. Specifically, Chapter 2 is a review of 
literature related to the thesis topic. All the original research data are covered in Chapters 3-5. The 
last chapter consists of the conclusion to the thesis and future prospects of the project. 
Chapter 2 describes the factors limiting the oral and brain delivery of peptides and introduces 
the glycosylation strategy as an effective system for the delivery of peptide-based therapeutics. 
Several methods of glycoconjugate synthesis and recent progress in the development of 
glycosylated peptides therapeutics have been also explained in this section. Moreover, the impact of 
glycosylation on changing the physicochemical properties and pharmacological profiles of peptides 
has been highlighted in this chapter. 
Chapter 3 is divided into two sections and describes the glycosylation of LHRH peptide and in 
vitro biological activity of the glycosyl-modified analogues. The first section is a published research 
article in the journal of ‘Bioorganic and Medicinal Chemistry’ and describes the design and 
synthesis of a library of LHRH analogues by the attachment of different sugar moieties such as 
glucose, galactose and lactose to the peptide sequence. This article also reports the in vitro 
biological evaluation of the glycosylated LHRH analogues including their metabolic stability in 
Caco-2 cell homogenate and apparent permeability across the Caco-2 cell monolayer model. The 
second section of Chapter 3 is an accepted manuscript in the journal of the ‘American Association 
of Pharmaceutical Sciences’. In this section, the metabolic stability of glycosylated LHRH 
analogues in different tissue homogenates including human plasma, rat kidney membrane and liver 
homogenates has been discussed. Their anti-proliferative effect on a number of tumour cell lines 
along with the toxic effect on normal peripheral blood mononuclear cells (PBMC) is also reported 
in this study. Additionally, the impact of selected analogues on stimulating the release of LH and 
FSH in the cultured rat pituitary cells is highlighted in the article. 
Chapter 4 includes a published research article in the journal of ‘Pharmaceutical Sciences’. 
This paper focuses on the role of glucose transporters (GLUT-2 and SGLT1) in the transport of the 
glycosylated LHRH derivatives. The role of efflux transport systems (P-gp and MRP2) in the 
extrusion of LHRH derivatives to the extracellular environment has been also described in this 
article.  
Chapter 5 describes the pharmacological evaluation of the lead compound, lactose-modified 
LHRH derivative, based on the preliminary studies. This article focuses on the PK parameters of 
this compound including bioavailability, half-life, and the maximum concentration (Cmax) and time 
to reach Cmax. The stimulatory effect of the lactose-modified analogue on the release of LH 
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hormone was also reported following oral administration to rats. This chapter was prepared as a 
research article which was submitted to the journal of ‘Pharmaceutical Research’. 
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Glycosylation, an effective strategy to improve the pharmacological properties 
of therapeutic peptides 
 
Abstract 
Given the advantages of peptides over conventional drugs, there is an increased interest in the 
development of peptides as therapeutic agents for the treatment of various diseases. However, 
several drawbacks such as undesirable physicochemical properties, short metabolic stability and 
low bioavailability hamper their clinical applications and successful development. Biological 
barriers are also formidable obstacles that impede the delivery of peptide drugs to the target site. 
Recent advances in the understanding of glycobiology together with synthetic methods in 
carbohydrate chemistry have had a great impact on the development of therapeutic peptides and 
proteins. Glycosylation of peptides is one of the promising strategies to modulate the 
physicochemical properties of peptide drugs and improve their absorption through biological 
membranes. This review summarises the biological barriers restricting oral and brain delivery of 
peptides. The effective impact of peptides’ glycosylation on overcoming the barriers is discussed. 
Various methods of glycoconjugate synthesis and the recent progress in the development of 
glycosylated peptide therapeutics are also described herein. 
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2.1 Introduction  
Peptides represent a promising therapeutic potential in the treatment of several types of disease 
with the low incidence of adverse effects (1). They offer several advantages over conventional 
therapeutic drugs including high activity, higher target specificity, low toxicity, and minimal non-
specific and drug-drug interactions (2, 3). Development of peptide-based therapeutics is one of the 
major goals of the pharmaceutical industry due to the various therapeutic potentials of these 
molecules for the treatment of diseases. Therefore, numerous attempts have been made to improve 
the pharmacological properties of peptide drugs and deliver them efficiently to the target sites 
particularly through non-parenteral routes (4-6). The poor physicochemical and pharmacological 
properties of peptides impede their efficient delivery. More importantly, peptide delivery through 
the oral route is the most persistent challenge due to the biological conditions such as variable pH, 
presence of proteases and physical barriers resulting in unfavourable conditions for successful 
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delivery (7, 8). The phospholipid bilayer in the biological membranes is a common barrier that 
limits the adequate penetration of peptide drugs inside the intestinal cells. Furthermore, inadequate 
absorption and rapid degradation by proteolytic enzymes are the other obstacles resulting in the low 
oral bioavailability of peptides (less than 1-2%) (8-10). 
Chemical strategies have been explored to overcome these obstacles and can be classified into 
two major groups: 1) chemical modification of peptides’ structure and 2) peptides’ formulation 
together with other components (absorption enhancers and enzyme inhibitors) in order to alter their 
unfavourable physicochemical characteristics (3, 11). Lipidation, glycosylation and cyclisation are 
some of the chemical approaches to improve the pharmacological profile of the therapeutic peptides 
(12-14). Among chemical modification strategies, incorporation of carbohydrate units into the 
peptides’ structure has become one of the most effective strategies of overcoming the related 
challenges (4). Attachment of glycosyl units to peptides causes several changes in their features 
including their conformational structures, their chemical, physical, and biochemical properties, as 
well as their functions (15, 16).  
This review provides insights into the barriers limiting the oral and brain delivery of peptides. 
The glycosylation strategy and the synthetic methods of glycoconjugate production have been 
described. The impact of glycosylation as an effective strategy on peptide delivery and the 
applications of this strategy towards the development of therapeutic peptides have also been 
discussed.  
 
2.2 Barriers limiting oral delivery of peptides  
Physical and biochemical barriers are major issues restricting the bioavailability of oral peptide 
drugs. Physical barriers include cell membranes and tight junctions between the epithelial cells and 
mucosa that hamper the diffusion of peptides into intestinal cells. Enzymatic digestion and first-pass 
metabolism are considered as biochemical barriers limiting the proper absorption of peptides. 
Enzymatic digestion of peptides results in a short half-life and the inability of the molecules to 
reach the site of action in adequate concentrations and produce the desired pharmacological effect.  
 
2.2.1 Mucus and unstirred water layer 
The whole area of intestine is coated with a stable layer containing mucus, water and 
glycocalyx. Mucus acts as a lubricant and protective barrier which is composed of a high molecular 
weight of a glycoprotein component called mucin (10). Mucus is a negatively charged layer which 
can interact with positively charged peptides and inhibit diffusion through the layer. Unstirred water 
layer (UWL) is a stringent aqueous layer which is a potential barrier to the absorption of drugs and 
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is considered as a diffusion barrier (12, 17, 18). The thickness of this layer is estimated to be about 
25µm in human jejunum (19). Early studies demonstrated that the absorption rate of the drug 
affected by UWL depends on the concentration of the solute and in higher concentrations, the 
permeation rate is not reduced (20). However, further studies showed that in vivo permeability of 
drugs is affected by this aqueous layer particularly for hydrophilic compounds (18, 21). In 
absorption of compounds like peptides and proteins, the mucus layer and glycocolyx are known as 
the first barrier (22) by which they retard the penetration of peptides through the intestinal 
membrane (23, 24). 
 
2.2.2 Epithelial cell membrane 
The membrane of the enterocyte in the gastrointestinal tract (GIT) is another formidable 
physical barrier in drug delivery research fields and the transport of peptides across the intestine is 
restricted by this membrane. Permeation of molecules across the intestinal epithelial cells 
(enterocytes) proceeds naturally by paracellular and/or transcellular pathways (8, 25). These 
pathways contribute to the penetration of drugs based on the physicochemical features of molecules. 
Generally, the paracellular pathway which comprises aqueous channels is involved in the transport 
of small hydrophilic components, whereas the hydrophobic molecules are typically transported 
through transcellular systems. Both pathways are size-dependent and limit the penetration of large 
hydrophilic molecules. 
 
2.2.2.1 Paracellular pathway  
This is an aqueous extracellular route between adjacent cells in the epithelia (Fig. 2.1-a). In this 
pathway, drug molecules pass through intercellular spaces where tight junctions exist and influence 
the permeation of passing molecules (26). The paracellular route has some advantages in the 
delivery of peptides because it provides an aqueous route and has no proteolytic activity (26, 27). 
However, the peptide transport through this route is restricted because of the small size of the 
aqueous channel. The channel pore size is estimated to be between 0.3 to 1 nm in humans (28) and 
it is just permeable to the peptides with a molecular weight of less than 100-200 dalton (Da) (26, 
29). The permeability of the solutes depends on influential factors such as the molecular weight and 
molecular size of the passing molecules (30). Tight junctions also act as charge (cation) selective 
channels to pass positively charged molecules through the spaces; however, the molecular size is 
dominant over the charge and the molecules larger than 200 Da cannot pass through tight junctions 
(31-33).    
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2.2.2.2 Transcellular pathway 
In this pathway, molecules cross the cells by means of passive diffusion, transcytosis and 
carrier-mediated transport (Fig. 2.1-b) (8, 12). The passive transcellular transport is non-saturable 
and non-sensitive to the stereochemistry of a drug, because there is no specific binding site in the 
lipid bilayer of the membranes (34). The transport occurs according to the concentration gradient of 
the solute from the higher to the lower concentration. This diffusion is suitable for the absorption of 
lipophilic drugs due to their affinity for the phospholipid bilayer. The size, charge and water-octanol 
partition coefficient (cLogP) of the molecules are also essential factors that affect the transport of 
the molecules through passive diffusion (34). Therefore, the Lipinski ‘rule of 5’ (Ro5) can be used 
to predict the ability of the drug to be diffused by passive transcellular transport (35). It was 
believed that this is the dominant route of the transport of drugs in the biological membrane (34). 
However, different carrier proteins are also involved in drug transport that could explain the 
possible permeation route of drug-like properties. It is believed that this mechanism contributes to 
the transport of biologically active peptides, the hydrophilic properties and large molecular size of 
which do not allow their transport through the lipid bilayer.  
Large size molecules can cross the epithelial membrane via a facilitative mechanism called 
transcytosis in which the macromolecules are taken up by vesicles. Transcytosis is an energy 
dependent mechanism and occurs vectorially in polarized cells like enterocytes. Receptor-mediated 
transcytosis and adsorptive transcytosis are two types of this system in which the ligands are 
internalized the cells through carrying vesicles (36, 37). The specifically bound ligands are 
transported through receptor-mediated pathways whereas non-specifically adsorbed ligands are 
internalized into the cells through adsorptive transcytosis. The transport of oligopeptides through 
the adsorptive mechanism has been reported in several studies (37, 38).  
The carrier-mediated transport system involves the transport of molecules through an active 
transport and facilitated diffusion mechanism by intervention of transmembrane proteins called 
transporters or carriers. The poorly absorbed molecules with hydrophilic property are mainly 
transported through this transport system. The system is divided into two groups of active transport 
and facilitated diffusion depending on the consumption of ATP as an energy source. Unlike passive 
diffusion, the carrier-mediated pathway is saturable and occurs when the concentration of the 
substrate is higher than the Michaelis constant (Km) (34). In the facilitated transport pathway, no 
energy source is required and the compounds pass through the membrane according to the 
concentration gradient; whereas, the active transport is energy-dependent and can transport the 
solutes against the concentration.  
There are more than 400 proteins classified into two major families of transporters: the ATP-
binding cassette (ABC) and the solute carrier (SLC) families (39, 40). The ABC transporter family 
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is an example of active transporters and requires the hydrolysis of ATP (primary active transport) to 
mediate the transport of the solutes (40). Many SLC transporters are involved in the uptake of 
various substrates including oligopeptides, glucose and other sugars, water-soluble vitamins, 
inorganic cations and anions (41, 42). SLC transporters can carry the substrate by different 
mechanisms including passive (uniport), coupled (symport) or exchange (anti-port) (43). Glucose 
transporters (GLUT) are an example of a uniport system. They transport sugars across the 
membrane according to their concentration gradient. Sodium sugar co-transporters (SGLT) and 
peptide transporters (PEPT1 and PEPT2) are among the coupled transporters. They carry substrates 
against the concentration gradient using the energy stored in the concentration gradient of the 
driving ion (Na
+
 or H
+
) (41). GLUT and SGLT are involved in the transport of carbohydrates and 
PEPT1 contributes to the transport of diverse peptide and peptidomimetic across intestinal 
membranes substrates (44, 45).  
Overall, the optimum physico-chemical properties of the drugs are required to take advantage 
of the transcelluar route. It has been reported that both passive diffusion and carrier- mediated 
transport cooperate in the permeation of drugs across biological membranes particularly through 
intestinal cells (34). 
 
 
2.2.3 Efflux drug transporters  
Efflux transport systems are classified in the family of ABC proteins and have an important 
impact on the disposition of orally administered drugs including peptides. These systems consist of 
several proteins that affect the intestinal absorption in combination with intracellular metabolising 
enzymes (e.g. cytochrome P450). Thus, they can change the pharmacokinetic features of therapeutic 
agents leading to their poor oral bioavailability (46). Multidrug resistance proteins (MRP) and P-
glycoprotein (P-gp) transporters are examples of these systems that are broadly studied. The main 
role of P-gp and MRP proteins is to extrude xenobiotics out of the cell leading to a restriction of the 
transcellular flux of drug molecules. P-gp and MRP2 are localized in the apical membrane of 
enterocytes whereas MRP1 are located on the basolateral side of the intestinal cells (46-49). It is 
believed that MRP1 is responsible for the extrusion of substrates into the blood. P-gp transporter is 
expressed not only in normal tissues such as the liver, kidney, brain endothelial cells and intestinal 
lumen, but also in cancerous cells. Therefore, it plays a pivotal role in resistance to anti-cancer 
therapeutic peptides (50).  
It has been illustrated that inhibition of efflux systems  improved the permeability of peptides 
across biological membranes significantly (51, 52). This supports the contribution of the efflux 
system in limiting the absorption of peptides through cell membranes. Cyclic peptides were also 
shown to be the substrates of the P-gp transporter and have a higher binding affinity to P-gp than 
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linear ones. Cyclosporine is an example of a cyclic peptide that is a proper substrate of efflux 
transporters (53). The hydrophobic residues in the peptides’ structure interact with P-gp and have a 
great impact on increasing the binding affinity to the transporter in both linear and cyclic constructs 
(54, 55).  
 
 
Figure 2.1. Barriers in oral delivery of peptide and proteins: A) Physical barriers limiting peptide 
transport through the intestinal membrane via: a) paracellular, and b) transcellular pathways, B) biochemical 
barriers comprised of metabolic digestion by brush border and/or intracellular metabolism and apical 
polarized efflux systems(10). P= peptide, M=metabolite 
 
2.2.4 Metabolic enzymes 
Enzymatic digestion is the other reason for the low bioavailability of orally administered 
peptides. Most compounds are affected by the enzymatic hydrolysis that occurs at the lumen, brush 
border membrane and cytosol. GIT contains various digestive enzymes including cytochromes P450 
(CYP450), transferases, peptidases and proteases that are involved in the digestion of therapeutic 
agents (56). Peptides are degraded in the lumen mainly by the proteolytic enzymes, trypsin, 
chymotrypsin, carboxypeptidase A and elastase secreted by pancreas (57). Elastase (serine 
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endopeptidase), trypsin and chymotrypsin are the examples of endopeptidases that hydrolyse the 
bond in the middle of a peptide sequence (58). 
The exopeptidases such as aminopeptidase A and dipeptidyl aminopeptidase are the enzymes in 
the brush border and the cytosol of enterocytes involved in peptide metabolism. These 
exopeptidases cleave the peptide bond at the NH2– or COOH–terminal of the peptide chain (58, 
59). Furthermore, lysosomal peptidases such as leukocyte elastase, cathepsins B and D are involved 
in the degradation of peptides endocytosed by epithelial or endothelial cells (60). 
 
2.3 Barriers limiting brain delivery  
For delivery of peptides to the central nervous system (CNS), it is necessary to overcome the 
blood brain barrier (BBB) which is a formidable obstacle to the passage of therapeutics into brain 
tissue. Similar to GIT, the BBB acts as both a physical and biochemical barrier towards the delivery 
of peptides to the brain and consequently restricts the absorption of the target drug. Endothelial cells 
in the brain contain proteolytic enzymes along with cytosolic enzymes  and polarized efflux systems 
that protect the brain from the entry of undesirable substances (61, 62). Moreover, brain capillaries 
are not only surrounded by endothelial cells, but are also covered by pericytes and astrocytic 
perivascular end-feet, which make a thick membrane around the capillary and restrict the transport 
of the molecules. On the other hand, the tight junctions between the endothelial cells of the brain 
have no fenestration which impedes the transport of the solute via the paracellular pathway (63, 64). 
The transport of drugs across the BBB occurs via two general pathways: 1) passive diffusion across 
the cell membrane and, 2) passage through specific transport systems. Drug molecules with a 
molecular size of smaller than 400 Da and bearing less than 8 hydrogen bonds may cross the BBB 
through passive diffusion. However, these properties are lacking in the majority of drug molecules 
(65). Due to relatively large and hydrophilic characteristics, peptides do not cross the BBB by 
passive diffusion and they require a particular transport mechanism to penetrate into the cells (66). 
The transport mechanisms including carrier-mediated transport, fluid phase endocytosis, 
transcytosis, adsorptive and receptor-mediated endocytosis are involved in the passage of the 
nutrients and small molecules to the brain (62, 66, 67). It has been shown that adsorptive mediated 
endocytosis and transcytosis mainly contribute to the penetration of the opioid peptide’s analogues 
across the BBB (68, 69). In addition, the BBB possesses proteolytic enzymes acting as metabolic 
barriers and causes the rapid degradation of the endogenous peptides (70). 
 
2.4 Role of glucose transporters in the transport of carbohydrates across biological 
membranes  
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Transport of hexoses across cell membranes is mediated by two different types of membrane 
protein families (GLUT and SGLT transporter families) in most mammalian cells (71). Glucose 
transporters are expressed in tissues and involved in the control of glucose homeostasis, i.e. muscle, 
adipose tissue, liver, intestine and brain (72). GLUT are Na+-independent facilitative transporters 
and they move the hexoses across the cell membranes according to their concentration gradient 
(73). GLUT transporters consist of 14 identified isoforms and they are classified in the SLC2 
transporters’ family. The distribution of the isoforms of these transporters differs in tissues and each 
transporter shows different affinities to hexoses. Based on the molecular structures, the isoforms are 
divided into three subclasses: class I comprises the classical transporters GLUT1–4 and GLUT14; 
the ‘‘odd’’ isoforms of GLUT5, 7, 9, and 11 belong to class II and class III contains the isoform 
GLUT6, 8, 10, 12 and the proton-driven myo-inositol transporter HMIT (GLUT13) (74). In 
addition to glucose, GLUT transporters mediate the transport of other monosaccharides including 
galactose, mannose, and fructose across cell membranes (72, 74). 
The other group of glucose transporters known as SGLT are Na
+
-dependent transporters and 
they are classified as the members of the SLC5 transporter family. SGLT transporters carry hexoses 
actively through cell membranes against the sugar concentration gradient by utilisation of the 
energy provided by Na
+
- K
+
 ATPase pumps (40, 45, 75). These transporters also contribute in the 
transport of amino acids, vitamins, osmolytes, and some ions across the intestinal brush border and 
renal tubules (76). Among all six identified isoforms, SGLT1 is the most known member involved 
in the transport of glucose across the intestinal brush border. SGLT1 has the same affinity for both 
glucose and galactose. SGLT2 is a high-capacity and low-affinity transporter located in the 
membrane of proximal renal tubules (77). It is responsible for a vast amount of D-glucose 
reabsorption in kidney (76, 78). SGLT3 is expressed in cholinergic neurons and skeletal muscles. 
Unlike the other members of this family, SGLT3 is not a glucose transporter and it seems to have a 
role as a glucose sensor (79). The functions of SGLT4, SGLT5, and SGLT6 are poorly understood 
(78). The detailed information concerning the structure and function of all GLUT isoforms has been 
extensively reviewed elsewhere (74, 80).  
The transport of carbohydrates in the intestine is mediated by both active transporters (SGLT) 
and facilitative transporters (GLUT) located on the epithelial cell membranes (73). In the intestine, 
SGLT1 and GLUT5 are located mainly on the apical side of the brush border of epithelial cells. 
GLUT2 is the dominant isoform of the transporter with a low affinity to glucose and resides in the 
basolateral side of enterocytes (Fig. 2.2) (40, 41). In response to high concentrations of sugar in the 
lumen, GLUT2 is transiently expressed on the apical surface of entrocytes and provides a chief 
pathway for carbohydrate absorption (41, 42). GLUT2 and SGLT1 transporters show different 
affinities for D-glucose and D-galactose. At low concentrations, glucose is transported against a 
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concentration gradient by SGLT1 (81), whereas, GLUT2 contributes to the glucose uptake at high 
concentrations of the sugar (82, 83). GLUT2 is also expressed in the basolateral surface of kidney 
absorptive cells and liver sinusoidal membrane where it is involved in blood glucose uptake (72). 
These transporters are useful targets to transport therapeutic peptides through biological 
membranes. For instance, Nomoto et al. showed that SGLT1 had an important role in the transport 
of glycosylated tetrapeptide (Gly-Gly-Tyr-Arg) which is not transported by di- or tripeptide 
transporters (84). The presence of D-fructose increases the level of GLUT5 mRNA confirming the 
role of this transporter in the intestinal absorption of fructose.(85) GLUT7, is another isoform of 
hexose transporters expressed in the apical membrane of intestinal cells and responsible for the 
transport of glucose and fructose (42). 
 
 
 
Figure 2.2. Localisation of  glucose transporters on the membrane of enterocytes (86): GLUT-2 is 
located on the basolateral side of the cells and mediates the transport of monosaccharides down their 
concentration gradient. SGLT-1 is located on the luminal (apical) side of the intestinal cells. 
Monosaccharides are co-transported with Na
+
 against their concentration gradient by contribution of this 
membrane transporter.    
 
 
In the brain, GLUT1 and GLUT3 are the main glucose transporters expressed in endothelial 
cells and neuronal cells, respectively. GLUT1 is the first identified isoform of the GLUT family and 
has been extensively studied. Two molecular forms of 45 (kilo dalton) kDa and 55 kDa exist in the 
brain in which they are localized at the perivascular end-feet of astrocytes and at the membranes of 
the endothelial cells, respectively (Fig. 2.3) (87). GLUT3 is localized at the neuronal cell membrane 
and mediates glucose transport from extracellular space into neuronal cells (88). It has been 
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suggested that the GLUT1 transporter is responsible for the improved uptake of glycosylated opioid 
peptide into the brain (43, 89).  
 
          
Figure 2.3 Localization of GLUT transporter isoforms in the brain: The 55-kDa form of GLUT1 is 
found in the endothelial cells, whereas the lower molecular weight of the 45- kDa form is expressed in 
astrocytes. The GLUT3 isoform is located in neuronal cells and it is responsible for the transport of glucose 
from extracellular spaces into the cells (87). 
 
It has been demonstrated that the isoforms of GLUT transporters such as GLUT1 and GLUT3 
are overexpressed in various cancer cells that can be used as a target for anticancer therapy and 
immunodiagnostic markers (90-93). It has been found that the overexpression of GLUT1 is 
associated with tumour progression and the reduced expression of GLUT1 suppresses the tumour 
growth in vitro and in vivo (92, 94, 95). SGLTs are also expressed on the tumour cell that can be 
targeted to deliver chemotherapeutic agents into the cancer cells (96). 
 
2.5 Glycosylation strategy for peptide delivery  
Carbohydrate moieties are used to change the physiological properties of peptides and improve 
their bioavailability. Some advantages of glycosylation include: 1) targeting specific organs and 
enhancing biodistribution in tissues (66), 2) improving penetration through biological membranes, 
3) increasing metabolic stability and lowering the rate of clearance (97), 4) improving receptor-
binding (98), 5) protecting amino acid’s side chain from oxidation, and 5) maintaining and 
stabilizing the physical properties of peptides such as precipitation, aggregation, thermal and kinetic 
denaturation (4, 99, 100). Conjugation of sugars with peptides can also facilitate the active transport 
of modified compounds across cell membranes by targeting glucose transporters on the surface of 
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biological membranes (101). The favourable impact of glycosylation on 
pharmacokinetic/pharmacodynamics properties of the indigenous peptides leads to an increase in 
their oral absorption and bioavailability. Glycosylated somatostatin is one pioneering example with 
potent biological activity through the oral route. The oral bioavailability of the modified peptide 
improved markedly which corresponded to the enhanced inhibitory effect on the release of growth 
hormone (102).  
 
 2.5.1 Glycopeptide synthesis 
The synthesis of glycoconjugates is a challenging process due to the presence of several 
functional groups (hydroxyl groups) in their structure. Therefore, the functional groups of the sugar 
moiety should be masked by permanent or temporary protecting groups to protect them from 
reacting with the reagents during synthesis (103). Benzyl ether and benzoyl ester are permanent 
protecting groups removed by reduction reaction at the end of the synthesis. Temporary groups such 
as trityl ethers, acetate and fluorenylmethyloxycarbonyl are removed during the intermediate steps 
of the synthesis. They are easier to cleave but stable during the synthesis (103, 104). Regio-
specificity (when only a single hydroxyl group is glycosylated) and streo-selectivity (when the β-
anomer is produced selectively) are two important factors in glycosylation reaction resulting in the 
production of higher yield of final products with reduction of producing side products. The type of 
protecting groups for masking the hydroxyl groups controls the regio-selectivity of the glycosides 
and determines their stereo-selectivity (103, 105).  
N- and O-linked glycosylation are naturally occurring processes in which carbohydrates are 
attached to polypeptide chains. This attachment can be through co-translational or post-translational 
modifications via either N- or O-glycosidic linkages (106). N-glycosylation occurs through the 
amine group of asparagine (Asn) residue resulting in the formation of an amide bond. In O-linked 
glycopeptide, the oxygen atom in the side chain of serine or threonine residues binds to the 
carbohydrate moiety through an ether bond (Fig. 2.4 A) (106-108). Synthetic glycopeptides are 
produced through a combination of the techniques used in carbohydrate and peptide chemistry. 
Generally, chemical and chemo-enzymatic methods are the reliable approaches for the synthesis of 
glycopeptides and glycoproteins.  
Direct and convergent syntheses are two common chemical strategies for N- or O-linked 
glycopeptides (Fig. 2.4B). In the direct method, the pre-synthesized glycosylated amino acid is 
coupled to the elongating peptide through solid phase peptide synthesis (SPPS) in a stepwise 
fashion (108). However, the synthesis of long peptides with more than 50 residues is difficult by 
this method due to the incomplete couplings and epimerization. This leads to the formation of side 
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products and a low yield of final product (105). Therefore, convergent (fragment–condensation) 
synthesis is applied as an alternative strategy to overcome this problem. The convergent approach is 
particularly used for N-linked glycopeptide synthesis as O-glycosylation is not achievable by this 
method (109). In the convergent method, the glycosylamine unit is conjugated to an aspartic acid 
containing peptide through condensation of the amino acid (110). This strategy is hampered due to 
the peptide’s racemization at the C-terminus and formation of aspartimides. To overcome the 
drawback, a modified convergent method has been employed in which pseudoproline motif is 
incorporated at Thr residues to avoid aspartimide formation (111).  
 
 
Figure 2.4: A) Examples of O-linked and N-linked glycosylated amino acids, B) Direct and convergent 
strategies for glycopeptide synthesis. 
 
In addition to O- and N-linked glycosylation approaches, several chemical methods have been 
established for the attachment carbohydrate units to different amino acid residues at N-terminus of 
peptide’s sequence. Conjugation of galactose unit to the N-terminus of α-melanocyte-stimulating 
hormone octapeptide analogue (NAPamide) is one of the examples in which the anomeric carbon of 
the carbohydrate was modified by ethanoic acid and attached to the N-terminus of NAPamide via 
the SPPS strategy (Fig. 2.5A) N-terminus modification of peptides is also achievable by 
conjugation of carbohydrate units to peptide through a succinamic linker. In this method, the azide 
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derivative of sugar moiety is replaced by succinamic acid at anomeric carbon and coupled to the N-
terminus of the peptide through a peptide bond (Fig. 2.5B). 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. The attachment of galactose residue to the N-terminal of A) NAPamide and B) LHRH 
peptides. A: Galactose was conjugated to the peptide through anomeric carbon modified by ethanoic acid 
(112); B: Sugar was attached to the peptide through a succinamic acid linker (113).  
 
Chemo-enzymatic approaches are powerful tools that combine the flexibility of chemical 
synthesis and high regio- and stereo-selectivity of enzyme-catalysed reactions to achieve highly 
efficient synthesis of complex carbohydrates. Particularly, these techniques are ideal choices for 
complex chemical synthesis like sialic acid-containing molecules or attachment of oligosaccharides 
to polypeptides (114). To date, several enzymes have been found with transglycosylation activity 
that can attach glycosyl moieties to peptides.  Endo-β-N-acetylglucosaminidases, Endo-A (form 
Arthrobacter) and Endo-M (from Mucor hiemalis) are common endoglycosidases with distinct 
substrate activity (115). These enzymes are able to couple an intact oligosaccharide to N-
acetylglucosamine (GlcNAc)-containing peptide or protein in a single step (116, 117). β-(1,3)-N-
(
B) 
(A) 
(B) 
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acetylglucosaminyltransferase (EC 2.4.1.56; LgtA) is an enzyme isolated from Neisseria 
meningitides and was used for the conjugation of GlcNAc residue to glycosylated endomorphin-1 
and lactose-enkephalin derivatives (118-120). Lipopolysaccharyl α-1,4-galactosyltransferase (EC 
2.4.1.; LgtC) is another glycosyltransferase derived from Neisseria meningitides and is applied for 
attachment of the galactose unit to the terminal lactose residue in lipooligosachharide (121). This 
enzyme was used to attach galactose residue to a glycosylated enkephalin to improve the metabolic 
stability of the peptide and target the ASGPR receptor (122). Using glycosyltransferases for 
glycosyl unit synthesis has some advantages including high yield and regio- and stereo-specificity 
without the need for protecting groups. Advances in the field of glycoconjugate synthesis will 
further improve the medical applications of these important and diverse biologically active 
molecules. 
 
2.5.2 Impact of glycosylation on physicochemical properties  
Physicochemical properties of peptide drugs play an important role in their pharmacokinetic 
profile and metabolic fate in the human body. Attachment of carbohydrate units to the peptides 
improves the physicochemical properties of the construct. Glycosylation can enhance the molecular 
stability and change the conformation of the peptide backbone (123-125).  Lin et al. showed that the 
modification of hamster prion peptide with different sugar entities such as mannose, galactose, and 
N-acetylgalactosamine (GalNAc) exerts diverse impacts on the conformational properties of the 
polypeptide chain. Mannosylation of the prion has an inhibitory impact on the formation of amyloid 
fibril (a special type of aggregation) implying the anti-aggregation function of this sugar entity on 
the prion peptide (125).  
It has been shown that the position of the glycosyl unit in the peptide’s structure is an important 
factor in changing the conformation of the peptide backbone and may affect the biological 
properties of the modified peptide. For instance, attachment of N-acetyl galactose amine (GalNac) 
to Thr
6 
and Thr
21
 in calcitonin peptide broke the helical structure of the intact peptide resulted in a 
reduction in receptor-binding affinity and loss of its bioactivity (126).  
 
2.5.3 Impact of glycosylation on pharmacological characteristics of peptides 
One of the main obstacles in the development of therapeutic peptides is their poor 
pharmacological properties. Glycosylation of peptides can modulate their 
pharmacokinetic/pharmacodynamic properties and improve their therapeutic efficacy. Several 
factors such as position, type and the number of carbohydrates are crucial to enhance the 
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pharmacological properties of the manipulated peptides and influence their biological functions 
(127).   
The position of the glycosyl unit attached to the peptide can influence the peptide-receptor 
interactions, biodistribution and pharmacological activity of the glycosylated peptides (70, 112, 
128). The structure-activity studies with enkephalin-based glycopeptides demonstrated that the 
position of the glycosyl units attached to the opioid peptides had different effects on binding affinity 
and the potency of the glycopeptide. The addition of β-D-glucose to the cyclized region of the 
opioid peptide Met-enkephalin decreased the binding to the receptor and eliminated its in vivo 
activity. Whereas, the glycosylation at position six of the linear peptide improved its analgesic 
activity significantly with retained receptor-binding affinity (129). If carbohydrate units are attached 
to peptides at the proper position, they preserve the structure-activity relations (SAR) of native 
peptide with the target receptor and enhance their biological activity (112). The site- dependent 
effect of glycosylation was also investigated for O-glycosylated calcitonin analogues and it was 
shown that glycosylation affects both the conformation and biological activity of calcitonin in a 
site-dependent manner (130). 
The type and number of carbohydrate (i.e. mono, di, and tri-saccharide) conjugated to the 
peptide can also influence its biological activity. Elmagbari et al. reported that the type of 
monosaccharide including α-mannose, β-xylose and β-glucose exerted different impacts on the 
opioid receptor-binding affinity of the hexapeptide (Tyr-D-Thr-Gly-Phe-Leu-Ser-CONH2). The 
best binding affinity was observed for the hexapeptide bearing β-glucose. Furthermore, conjugation 
of disaccharide to the hexapeptide caused a higher antinociceptive activity than the 
monosaccharide-bearing analogue after intravenous administration (131). The impact of 
carbohydrate type (glucose, galactose and mannose) on renal delivery of arg-vasopressin (AVP) 
peptide was studied in rats. The glucose and mannose derivatives of AVP peptide exhibited higher 
renal uptake than the galactose-modified analogue. It was also shown that the glucosyl and 
mannosyl conjugates that was bound specifically to the kidney microsomal membrane in vitro 
resulted in high renal uptake (132).  
The attachment of tri-saccharide (galactose-lactose) to enkephalin resulted in a higher binding 
affinity to the asialoglycoprotein receptor compared to the galactose-modified analogue. The 
enzymatic stability of the trisaccharide (galactose-lactose) conjugated enkephalin in human plasma 
and Caco-2 cell homogenate improved significantly compared to the peptide alone (133). The 
higher number of sugar units is not always accompanied by an improvement in the biological 
properties of the modified peptides. A single GlcNAc unit attached to calcitonin had the best 
hypocalcemic effect with improved biodistribution of the peptide; whereas, increasing the number 
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of carbohydrate moieties (multiple copies of mannose and GlcNAc) decreased the activity of 
calcitonin (130). 
Improving the metabolic stability of peptide drugs is another advantage of glycosylation   
leading to enhance their in vivo bioavailability. Typically, endogenous peptides have short half-lives 
in the biological environment due to the enzymatic digestion. Incorporation of carbohydrate units to 
peptides can protect them from proteolysis without changing their bioactivities (113, 134-139).  
Different strategies of glycosylation (N-linked, O-linked or N-terminal glycosylation) have 
been applied for improving the metabolic stability of modified peptides both in vivo and in vitro. 
Introduction of O-β-glucosylated serine glucose (Ser(Glc)) to the analgesic compound TY027 (Tyr-
D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-3´,5´-Bzl(CF3)2) at position six  (O-linked glycosylation) 
enhanced its metabolic stability significantly (128). The longer serum half-life was reported for 
Major-Histocompatibility-Complex (MHC)-binding peptides (MHC receptor inhibitors) following 
glycosylation. Substitution of valine with N-acetyl glucosamine-modified Asn in (MHC)-binding 
peptide (N-linked glycosylation) stabilized the modified peptide against serum peptidases 
significantly compared to the unmodified analogue (134). N-terminal modification of glucagon-like 
peptide 1 (GLP-1) with glucitol residue improved the resistance of the compound to enzymatic 
degradation after intraperitoneal administration to Wistar rats (135). In another study, the 
attachment of sialyl N-acetyllactosamine (lacNAc) to Asn residue of GLP-1 peptide via N-linked 
glycosylation improved the in vivo stability of the modified peptide and prolonged its anti-
hyperglycaemic activity (136).  
N-terminal attachment of the glycosyl unit to endomorphine-1 via the succinamic acid linker 
improved the metabolic stability of the peptide in human serum significantly (137). The same 
strategy was applied for N-terminal modification of LHRH which resulted in significant 
enhancement in the metabolic stability of the modified peptides in Caco-2 cell homogenate 
(containing a series of proteolytic enzymes) (113).  
Improving the penetration of peptides across biological membranes is another advantage of 
glycosylation. Glycosylation of endomorphine-1 resulted in a 700-fold increase in membrane 
permeability across the Caco-2 cell monolayer. It was suggested that this analogue was transported 
across membranes through a lactose-selective transporter (137). N-terminally modified LHRH with 
sugar moieties including glucose, galactose and lactose had a significant impact on improving the 
permeability of the analogues through the Caco-2 cell monolayer (113). It was reported that GLUT2 
and SGLT1 contributed to the transport of the glycosylated LHRH analogues across Caco-2 cell 
membranes. It was also shown that the efflux pumps (P-gp and MRP2 transporters) did not affect 
the apparent permeability of any of the glycosylated analogues except for the galactose derivative 
(52). 
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 2.6 Development of therapeutic peptides using glycosylation strategy 
2.6.1 Neuropeptide therapeutics 
Neuropeptides have therapeutic potential for the treatment of neurological disorders.  However, 
the successful delivery of these peptides to the CNS has been hampered due to formidable obstacles 
like the BBB, enzymatic digestion and liver clearance limiting the efficient delivery of peptides to 
the brain (140, 141). Glycosylation has been shown to be one effective strategy to improve brain 
delivery of therapeutic peptides. This approach promotes the penetration of opioid peptides 
including enkephalins, endorphins and dynorphins into the brain and increases their 
pharmacological activity. Therefore, the glycosylated analogues of opioid peptides have shown 
improved analgesic activity (129, 137, 142, 143). Enkephalin is a pentapeptide involved in 
antinociception with a short half-life in blood and an inability to pass the BBB. Attachment of 
Ser(Glc) residue to Lue-enkephalin amide (Tyr-D-Thr-Gly-Phe-Leu-Ser-NH2) improved the 
permeability of the opioid peptide across the BBB in mice. The glycosylated analogue produced a 
similar antinociceptive effect to morphine (144).  
The improved permeability and higher metabolic stability of the glycosylated neuropeptides 
results in a significant increase in their bioavailability that might account for the enhanced analgesic 
effect of the glycopeptides (64, 143). The decreased renal clearance of glycosylated analogue of 
Met-enkephalin (conjugated β-D glucose) resulted in significant improvement in the bioavailability 
and analgesic effect of the peptide in rats (142). Conjugation of lactose succinamic acid to 
endomorphine-1 produced a significant analgesic activity after oral administration in a chronic pain 
model in rats and the modified peptide showed a significant change in binding-affinity to μ-opioid 
receptor (137). It is postulated that glycopeptides penetrate the BBB through adsorptive endocytosis 
(145). However, the exact mechanism involved in improving the permeation of the glycosylated 
peptides through biological barriers is yet to be elucidated.  
 
2.6.2 Radiopharmaceuticals  
Glycosylation is a promising strategy for improving the biodistribution and poor 
pharmacological profiles of the radiolabeled peptides for diagnostic and therapeutic purposes. The 
radiolabeled derivatives of bombesin peptide have potential applications in cancer cell imaging and 
peptide receptor radiotherapy. However, they possess unfavourable pharmacokinetic properties 
such as hepatic accumulation and hepatobiliary excretion (146). Conjugation of radiolabeled 
bombesin analogues with glucose moiety (through a traizole group) reduced the abdominal 
accumulation and increased the tumour uptake without affecting the cell internalization of the 
modified peptides (147). Glycosylation was applied to increase the hydrophilic property of 
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radiolabeled Tyr
3
-octreotide peptide and overcome the drawbacks restricting its diagnostic 
application in cancer radiotherapy. Carbohydrate modifications of the peptide using glucose, 
maltose and maltotriose resulted in a higher renal clearance and subsequently less accumulation of 
the peptide in the liver and abdominal region. This modification made Tyr
3
-octreotide analogues 
(particularly maltose and glucose-conjugated peptides) suitable for targeted imaging and 
radiotherapy of somatostatin receptor-expressing tumours (148).   
In another study, the radiolabeled arginine–glycine–aspartic acid (RGD)-containing 
pentapeptide (cyclysed (Arg-Gly-Asp-D-Tyr-Lys) was glycosylated to improve the pharmacokinetic 
profiles of the modified analogues. These peptides are antiangiogenetic agents and act as an 
antagonist of an integrin glycoprotein (αVβ3) expressed in malignant tumour cells. It was observed 
that conjugation of GlcNAc to Lys residue of the peptide decreased its lipophilicity and reduced the 
hepatic uptake of the modified peptide leading to a significant increase in tumour uptake (149).  
 
2.6.3 Targeted delivery  
Carbohydrate-mediated delivery also termed as glycotargeting is a strategy that employs cell 
surface recognition in order to target specific organs. Carbohydrates are useful candidates for 
receptor-targeted peptide delivery as their receptors, known as lectin receptors, are expressed in the 
membrane of different cells such as liver, tumour cells, and kidney. Therefore, the therapeutic 
agents conjugated with carbohydrate units can be recognized by those receptors and internalized 
into the cells (150). Asialoglycoprotein receptor (ASGPR) is a lectin receptor expressed on the 
surface of liver hepatocytes that recognizes the galactose and the galactosyl residue of the 
glycoproteins (150, 151). ASGPR can be targeted for peptide delivery to the hepatocytes. Reports 
indicated that kidney and brain targeting of peptides are also achievable through a glycosylation 
strategy. Suzuki et al. showed that the mannose and glucose derivatives of arg-vasopressin had high 
in vivo renal uptake (132).  
Glucose transporters such as GLUT1 and GLUT3 are overexpressed in various cancer cells that 
can be targeted for anticancer therapy and immunodiagnostic markers (90-93). It has been found 
that the overexpression of GLUT1 is associated with tumour progression and the reduced 
expression of GLUT1 suppresses the tumour growth in vitro and in vivo (92, 94, 95). 
Glycopeptides can also target specific cancer cells. The impact of galactose and glucose 
matotriose on the pharmacokinetic properties of α-melanocyte-stimulating hormone (α-MSH) was 
evaluated to target melanoma cancer. It was shown that the glycosylated analogues exhibited 
excellent binding affinities (in nanomolar and subnanomolar ranges) to the specific receptor 
(melanocortin receptor 1 (MC1R) overexpressed in melanoma cells) in vitro. Among all 
glycopeptides, the analogue-bearing galactose unit at the N-terminus of the peptide had a favourable 
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pharmacokinetic profile (higher tumour uptake with a lower kidney uptake) for melanoma targeting 
(112). 
  
2.7 Conclusion 
The successful development of peptide-based therapeutics requires the optimization of their 
pharmacological profiles. Glycosylation can be applied to enhance the therapeutic behaviour of 
peptide drugs by optimizing their pharmacokinetic and pharmacodynamic properties. Incorporation 
of carbohydrate moieties into the peptides’ sequence can change their physicochemical properties 
leading to increasing the membrane permeability across biological membranes and improving their 
proteolytic stability against digestive enzymes. The significant therapeutic potential of glycosylated 
peptides accounted for the establishment of several techniques for the synthesis of glycoconjugates 
which had an important impact on the development of carbohydrate-based peptide drugs. Further 
advancements in understanding the fundamental impact of glycosylation on the pharmacological 
properties of peptides are still required for the rational design of glycopeptides with enhanced 
biological activity. 
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Chapter 3: Glycosylated LHRH analogues and 
their biological properties 
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3.1 Introduction to this publication 
 
This section was published as a research article in the journal of ‘’Bioorganic and Medicinal 
Chemistry’’. In this article, the synthesis of the glycosylated LHRH derivatives by the attachment of 
different sugar moieties including lactose, galactose and glucose was described. 
The in vitro biological properties of the glycosyl conjugates of LHRH including their metabolic 
stability in Caco-2 cell homogenate and their membrane permeability across Caco-2 cell monolayer 
were investigated and reported in this publication. 
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 2013 Elsevier Ltd. All rights reserved.1. Introduction
Luteinizing hormone-releasing hormone (LHRH), also known as
gonadotropin releasing hormone (GnRH), is a neuropeptide that
plays an important role in regulating the reproductive system.1 It
is produced by neurosecretory cells in the hypothalamus and
mediates its effect by binding to the cognate receptor on gonado-
trope cells in the pituitary gland, where it stimulates the secretion
of luteinizing hormone (LH) and follicle-stimulating hormone
(FSH). The release of FSH and LH controls the secretion of sex ste-
roid hormones in the gonads.1,2
LHRH is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-
Gly-NH2, Fig. 1) and has a short half-life of 3–4 min in human plas-
ma due to the rapid enzymatic degradation.3,4 It is mainly cleaved
by a metalloendopeptidase called EP24.15 at position six (Tyr5–
Gly6), prolyl endopeptidase (PE) at position nine (Pro9–Gly10) and
pyroglutamyl peptidase that cleaves pGlu residue at position one
(pGlu1–His2) of the peptide sequence.5–7
Elucidation of the structure of LHRH by Schally et al. in 19718
prompted the development of several LHRH analogues, which have
a variety of applications in the treatment of hormone-dependent
diseases such as prostate cancer, precocious puberty, endometri-
osis and breast cancer. All clinically approved analogues currently
on the market are administered daily, either parenterally or intran-
asaly.9–11 Oral administration has advantages in terms of patientcompliance and ease of treatment. Therefore, orally available LHRH
analogues are highly desirable. However, the development of orally
active LHRH derivatives has been hampered by poor stability and
bioavailability in vivo. Hence, for oral delivery, it is necessary to
improve the pharmacokinetic proﬁle of LHRH to enable transport
to the target site in an adequate concentration.
Physical and biochemical barriers are major issues restricting
the oral bioavailability of peptide drugs.12 Physical barriers, includ-
ing the mucosa, cell membranes and tight junctions between epi-
thelial cells, impede the absorption of peptides from the
gastrointestinal (GI) tract.13 Digestive enzymes in the GI tract have
an important impact on peptide drugs, decreasing the half-life and
affecting their ability to reach the site of action in an adequate con-
centration after oral administration.12,14 The intact LHRH peptide
passes the blood brain barrier (BBB) via a saturable transport sys-
tem.15–17 The principal factors impeding drug absorption in the
central nervous system (CNS) include proteolytic enzymes in brain
endothelial cells, and an apically polarised efﬂux system that
pumps the solute back to the blood circulation.18,19
To date, several strategies have been explored to overcome the
challenges presented by delivering peptides orally. Among them,
chemical modiﬁcation of peptide sequences (e.g. attachment of li-
pid and carbohydrate moieties or amino acid substitution) is con-
sidered to be an effective approach, enhancing bio-distribution of
the target peptide by changing its pharmacodynamic and pharma-
cokinetic properties.20,21 Substitution of L-amino acids with
D-amino acids is a common method of chemical alteration which
protects peptides from proteolysis and can stabilise the desired
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Figure 1. Structure of LHRH.
4260 S. V. Moradi et al. / Bioorg. Med. Chem. 21 (2013) 4259–4265conformation.22 Attaching carbohydrates to C-terminus, N-termi-
nus or the middle of the peptide sequence is another method that
can increase the metabolic stability of the peptide, and improve its
absorption across biological barriers.23–26
The purpose of this study was to examine the role of carbohy-
drate moieties in improving the metabolic stability and in vitro
permeability of LHRH. Therefore, we synthesized a small library
of LHRH derivatives by conjugating carbohydrate moieties to either
the N- or C-terminus of the peptide sequence. We also synthesized
an analogue which was modiﬁed by substituting the amino acid
sequence in addition to the attachment of a sugar moiety to its
N-terminus. The analogues were analysed using established
in vitro assays to assess their stability against enzymatic metabo-
lism (exposure to Caco-2 cell homogenate), and their permeability
across biological barriers (Caco-2 cell monolayer permeability).
2. Results and discussion
2.1. Design and synthesis of glycosylated derivatives of LHRH
The glycosylated LHRH analogues that were synthesized using
solid phase peptide synthesis (SPPS) are shown in Table 1. Com-
pound 1, native LHRH, was used as a control. In compound 2, pyro-
glutamic acid (pGlu) at position one was replaced with glutamic
acid (Glu). Carbohydrate units were made compatible with SPPS
by modiﬁcation with a succinamic acid linker (for N-terminus
attachment) or an azide (for C-terminus attachment) at the ano-
meric carbon in four synthetic steps. For the synthesis of com-
pounds 3–5, pyroglutamic acid (pGlu) was substituted with
glutamic acid (Glu) at position one, to provide a free amine group
at the N-terminus to allow attachment of lactose (3), galactose (4)
or glucose (5). The synthesis of compound 6 was done by addition
of glucoronic acid to C-terminus of LHRH. Two main changes were
performed for the synthesis of compounds 7–9. Instead of glutamic
acid, glutamine was added in position one, then the N-termini of
those compounds were modiﬁed by attachment of glycosyl units.
The reason for replacement of glutamic acid with glutamine at po-
sition one was because of faster cyclisation of glutamine compared
to glutamic acid at physiological pH.27,28 Furthermore, the natural
sequence of the LHRH prohormone contains glutamine instead of
glutamic acid which is cyclised when the hormone converts to
the biologically active peptide.29
As described in the introduction, Tyr5–Gly6 is the main cleavage
site of LHRH.5,7 It is well-known that substitution of glycine in po-
sition six with a D-amino acid results in increased metabolic stabil-
ity and lipophilicity.30,31 Moreover, placing D-amino acid residue at
position six generates agonist derivatives of LHRH with high recep-46tor binding afﬁnity due to the stabilisation of a conformation
important for receptor binding.9,32 Compound 11 was synthesised
by the replacement of Gly with D-Trp at position six and conjuga-
tion of the succinamic acid derivative of lactose at its N-terminus.
Compound 10 (the commercially available analogue-triptorelin)
was synthesised by substitution of Gly with D-Trp at position six
for comparison with compound 11.
All of the peptides were synthesised on Rink amide MBHA resin
using Fmoc chemistry via standard solid phase peptide synthesis.33
The crude peptides were then puriﬁed using preparative HPLC,
characterised by electrospray ionisation mass spectrometry (ES-
MS).2.2. Caco-2 cell monolayer permeability assay
Due to similarities with human intestinal epithelium, Caco-2
cell monolayers are routinely used in pharmaceutical research
as a useful model to predict the transport of drug molecules
across biological barriers.34,35 The apparent permeability of LHRH
analogues was examined using Caco-2 (Fig. 3) cell monolayer at
pH 7.4 and 37 C to mimic conditions similar to those of the
physiological environment. Freshly prepared Hank’s balanced
buffer solution (HBSS) in 25 mM of N-2-hydroxyethylpiperazine-
N0-2-ethanesulfonic acid (HEPES) buffer was used to keep the
pH within this range during the test. Furthermore, the compound
solutions were prepared in HBSS/25 mM HEPES. The integrity of
tight junctions within the monolayer was evaluated using trans-
epithelial electrical resistance (TEER) values before and 24 h after
the experiment. Values obtained after performing the test were
within 15% of those measured before the start of the experiment.
This conﬁrmed that the cells were stayed quite intact and none of
the compounds were toxic and damaging to the cell. Additionally,
[14C]mannitol was used as a paracellular ﬂux marker to show
that the cell monolayer remained intact. This assay was
repeated twice independently and in triplicate for each tested
compounds.
The parent peptide (compound 1) had very low permeability of
3.98  107 cm/s (Fig. 2). Among all tested compounds, the appar-
ent permeability of compounds 3, 5 and 9 increased signiﬁcantly
(One-way ANOVA, p <0.05) by approximately 6–7-fold compared
with the native peptide. The permeability of compound 8
(16.2 ± 2.23  107 cm/s) was also higher than that of the native
peptide (1). The apparent permeability of analogue 4 was about
three times higher than LHRH, however this increase was not sta-
tistically signiﬁcant. The permeation rate of analogue 7 did not
change notably compared with peptide 1.
Table 1
Structure of LHRH analogues
Compound Structure
1
2
3
4
5
6
7
8
9
10
11
S. V. Moradi et al. / Bioorg. Med. Chem. 21 (2013) 4259–4265 4261The Caco-2 cell monolayer permeability assay has known limi-
tations. For example the underestimation of carrier-mediated
transport due to low expression of transport proteins36,37 and over-
expression of the efﬂux transporter P-glycoprotein.38 Nevertheless,
we observed a considerable increase in the transport of most su-
gar-conjugated LHRH analogues across the Caco-2 cell monolayer.
2.3. Caco-2 cell homogenate stability assay
The in vitro stability of carbohydrate conjugated LHRH was
tested using Caco-2 cell homogenates. Well-differentiated Caco-2
cells express a series of proteolytic enzymes that may be a good
model for investigating the metabolic proﬁle of potential therapeu-
tic peptides.39 In this assay, the stability of all compounds were
tested in quadruplicate and repeated three times independently.
Caco-2 cells were lysed and separated from cell debris by centrifu-47gation to prepare the soluble fraction of the cell homogenates.
Among all derivatives of [E1]LHRH, compound 3 (modiﬁed with
lactose at the N-terminus) had the highest stability (t1/
2 = 77 min). Compound 6 showed the lowest half-life at t1/
2 = 28.4 min, which was even lower than that of the native peptide.
Our results are consistent with previous studies that indicated that
the stability of peptides with C-terminal carbohydrate modiﬁca-
tions is quite similar to the parent peptide.40,41
We also observed a signiﬁcant increase in the half-life of all su-
gar conjugated analogues of [Q1]LHRH. In particular, (Table 2) ana-
logue 7 was the most stable compound (t1/2 = 133 min) in Caco-2
cell homogenate. Although compound 11 was less stable than
compound 10, it exhibited a signiﬁcant improvement in stability
of approximately fourfold when compared with LHRH. The half-life
of each analogue is presented in Table 3. The half-life of endoge-
nous LHRH in Caco-2 cell homogenates was found to be 32.7 min
0
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Figure 2. Apparent permeability of sugar-conjugated LHRH in Caco-2 cell mono-
layer. Statistical analysis was performed using one-way ANOVA analysis followed
by Dunnet post-test. Each value represents mean ± SEM (n = 2 independent
experiments in triplicate for each compound). ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, and ns
p > 0.05, analogues vs LHRH.
4262 S. V. Moradi et al. / Bioorg. Med. Chem. 21 (2013) 4259–4265which is higher than the half-life measured in the human body (t1/
2 = 3–4 min).3 It has previously been shown that this cell line lacks
several metabolic enzymes.42,43 Additionally, it is possible that
in vivo a large proportion of LHRH is cleared from systemic circu-
lation by renal or biliary excretion.3,43,44
2.4. Release pattern of the parent peptide by LHRH analogues
In addition to investigating the stability of the tested com-
pounds, the level of parent LHRH peptide released from the ana-
logues was also measured in order to investigate whether any of
the modiﬁed compounds could act as a prodrug. Minimal levels
of native peptide were detected for any of the analogues (Fig. 4).
It is possible that the rate of LHRH release is too slow to be de-
tected during the limited time of the experiment (2 h). It is also0 20 40 60 80 100 120 140
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Figure 3. Degradation proﬁle of LHRH analogues in Caco-2 cell homogenate: (A) percent
[Q1]LHRH derivatives remaining in cell homogenate, (C) percentage of 10 and 11 remai
independent experiment) and analysed by one phase decay analysis using Graphpad Pr
48possible that the Caco-2 cell homogenates lack the enzymes neces-
sary to cleave the derivative to liberate the LHRH peptide.
3. Conclusions
We successfully synthesised and puriﬁed a small library of car-
bohydrate conjugated LHRH analogues. Based on the results of
in vitro assays performed, we conclude that modiﬁcation of the
N-terminus of LHRH with carbohydrate improved its in vitro bio-
availability both by stabilizing the peptide towards enzymatic
digestion and increasing its permeation across the Caco-2 cell
monolayers. Coupling carbohydrate to the N-terminus of the pep-
tide (e.g. 3) decreased its degradation by endonucleases in Caco-2
cell homogenates. It was also observed that all the derivatives
modiﬁed with lactose succinamic acid (Compounds 3, 7 and 11)
exhibited higher stability compared with analogues conjugated
to other sugar moieties. Data analysis of the permeability assay
also indicated a signiﬁcant enhancement in absorption of N-termi-
nal glycosylated LHRH peptides with the exception of compound 7,
which exhibited low permeability.
The in vitro–in vivo correlation studies show that the transport
rate of the compounds with high permeability coefﬁcient of
(Papp > 1  106 cm/s) is twofold to fourfold less than the rate in
human jejunum in situ.34 As the permeability co-efﬁcient of the
most of our derivatives was higher than the mentioned rate, we
anticipate a signiﬁcant increase in oral absorption when these ana-
logues are tested in vivo.
4. Experimental
4.1. General
Fmoc-protected amino acids and Rink amide MBHA resin
(100–200 mesh, 0.59 mmol/g) were purchased from Novabiochem
(Melbourne, Australia) or Mimotopes (Clayton, VIC, Australia).0 20 40 60 80 100 120 140
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Table 2
Characterisation of glycosylated LHRH analogues
Compound Pure ﬁnal yield (%) HR-MS Retention time (tR) on RP-HPLC (min)
Calculated Found
1 48 [M+H]+ 1182.5803 1182.5805 13.8
2 45 [M+2H]+ 600.7791 600.8008 13.6
3 31 [M+2H]+ 812.3679 812.3672 13.6
4 36 [M+2H]+ 731.3415 731.3450 13.5
5 39 [M+2H]+ 731.3415 731.3431 13.5
6 22 [M+2H]+ 688.3231 688.3258 13.2
7 26 [M+2H]+ 811.8759 811.8789 13.2
8 34 [M+2H]+ 730.8495 730.8530 13.3
9 27 [M+2H]+ 730.8495 730.8530 13.2
10 68 [M+H]+ 1311.6382 1311.6406 15.7
11 17 [M+H]+ 1751.8012 1751.8012 15.6
Table 3
The half-life of glycosylated LHRH analogues in Caco-2 cell homogenate and their
permeability across the Caco-2 cell monolayer. Data of stability assay was obtained by
LC–MS analysis and values are mean ± SD (n = 3). Each sample was tested in 4
replicates and the experiment was independently repeated three times. ND, not
determined.
Compound Peptide derivatives Half-life (min) Papp (107 cm/s)
1 [pE1]LHRH 32.6 3.98 ± 0.96
2 [E1]LHRH 30.4 ND
3 Lactose-[E1]LHRH 77.0 28.7 ± 0.56
4 Galactose-[E1]LHRH 51.0 10.8 ± 1.23
5 Glucose-[E1]LHRH 56.7 26.5 ± 3.27
6 [E1]LHRH-Glucoronic acid 28.4 ND
7 Lactose-[Q1]LHRH 133.0 7.6 ± 1.73
8 Galactose-[Q1]LHRH 92.2 16.2 ± 2.23
9 Glucose-[Q1]LHRH 73.5 23.1 ± 1.29
10 [pE1][w6]LHRH 185.7 ND
11 Lactose-[Q1][w6]LHRH 132.8 ND
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propylethylamine (DIPEA) and piperidine of peptide synthesis
grade were obtained from Merck Biosciences (Kilsyth, VIC, Austra-
lia) or Sigma–Aldrich (VIC, Australia) and O-benzotriazole-
N,N,N0,N0-tetramethyl-uronium-hexaﬂuoro-phosphate (HBTU) was
purchased from Mimotopes (Melbourne, Australia). HPLC-grade0 20 40 60 80 100 120 140
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Figure 4. Level of native LHRH released from glycosylated analogues of LHRH in Caco-2 c
in any of the tested compounds. Data is presented as the mean ± SD (n = 3, independent
49acetonitrile was purchased from RCI Labscan Ltd, (Bangkok,
Thailand). All media and supplements for cell culture work were
purchased either from Sigma–Aldrich or Life Technologies (VIC,
Australia). Caco-2 cells were obtained from American Type Culture
Collection (Rockville, USA).
1H nuclear magnetic resonance (1H NMR) spectra were re-
corded on Bruker Avance 300 MHz spectrometer (Bruker Biospin,
Germany). Peptides were characterised by electrospray ionisation
mass spectrometry (ES-MS) on a PE Sciex API3000 triple quadru-
pole mass spectrometer using a mixture of solvent A1 (0.1% acetic
acid in water) and B1 (0.1% acetic acid in 9:1 acetonitrile/water) at
0.05 mL/min. The Varian Cary 50 Bio UV/vis spectrophotometer
(k = 570 nm) was used for absorbance measurements. LC–MS was
carried out using solvents A1 and B1 at a ﬂow rate of 0.5 mL/min,
and a splitter after the Phenomenex Luna C18 column (5 lm,
50  2.0 mm) was used to achieve a ﬂow rate of 0.05 mL/min in
the ion source of the mass spectrometer. Analytical HPLC was per-
formed on an Agilent 1100 system ﬁtted with a binary pump, auto-
sampler, and a UV detector set to a wavelength of 214 nm.
Preparative RP-HPLC was performed on a Shimadzu instrument
(Kyoto, Japan; LC-20AT, SIL-10A, CBM-20A, SPD-20AV, FRC-10A)
in linear gradient mode using 20 mL/min ﬂow rate, with detection
at 230 nm. Separations were performed with solvent A2 (0.1% TFA
in water) and solvent B2 (0.1% TFA in 9:1 acetonitrile/water) on Vy-
dac preparative C18 column (218TP1022; 10 lm, 22  250 mm).0 100 120 140
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ell homogenate. The carbohydrate moieties were not cleaved from the LHRH peptide
experiment) using Graphpad Prism 5.
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Succinamic derivatives of the carbohydrates were synthesized
in four steps according to published methods.45–49 The azide deriv-
ative of glucoronic acid was synthesized according to the protocol
described in the literature.46
4.2.1. 4-Oxo-4-[(2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl)-
amino]-butanoic acid
C18H25O12N, 447.40; melting point: 152–155 C; ES-MS, m/z:
448.3 [M+H]+, 470.1 [M+Na]+, 895.5 [2M+H]+, 917.7 [2M+Na]+.
NMR data correspond to those reported in literature.48
4.2.2. 4-Oxo-4-[(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-
amino]-butanoic acid
C18H25O12N, 447.40; melting point: 142–143 C; ES-MS, m/z:
448.2 [M+H]+, 470.2 [M+Na]+, 895.5 [2M+H]+, 917.7 [2M+Na]+.
NMR data correspond to those reported in literature.45
4.2.3. 4-Oxo-4-[(2,3,6-tetra-O-acetyl-4-O-20,30,40,60-tetra-O-
acetyl-b-D galactopyranosyl-b-D-glucopyranosyl)amino]
butanoic acid
C30H41NO20; melting point: 97–98 C. ES-MS, m/z: 736.3
[M+H]+, 758.3 [M+Na]+, 781.6 [M+2Na]+ 1472.2 [2M+H]+. 1H
NMR (300 MHz, CDCl3): d = 6.44 (d, 1H, JNH,1 = 9.3 Hz, NH), 5.35
(dd, 1H, J40 ,50 = 1.0 Hz, J30 ,40 = 3.5 Hz, H-40), 5.29 (dd, 1H,
J3,4 = 8.9 Hz, J2,3 = 9.6 Hz, H-3), 5.22 (dd, 1H, JNH,1 = 9.3 Hz,
J1,2 = 9.3 Hz, H-1), 5.10 (dd, 1H, J10 ,20 = 7.9 Hz, J20 ,30 = 10.4 Hz, H-20),
4.95 (dd, 1H, J30 ,40 = 3.5 Hz, J20 ,30 = 10.4 Hz, H-30), 4.84 (dd, 1H,
J1,2 = 9.6 Hz, J2,3 = 9.6 Hz, H-2), 4.47 (d, 1H, J10 ,20 = 7.9 Hz, H-10),
4.43 (m, 1H, H-6a), 4.14 (m, 2H, H-6b,H-6a0), 4.07 (m, 1H, H-6b0),
3.87 (m, 1H, H-50), 3.76 (dd, 1H, J3,4 = 8.8 Hz, J4,5 = 8.8 Hz, H-4),
3.73 (m, 1H, H-5), 2.72 (m, 1H, CH2CO), 2.63 (m, 1H, CH2CO),
2.47 (m, 2H, CH2CO), 2.15 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.07 (s,
3H, OAc), 2.05 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc),
1.96 (s, 3H, OAc).
4.3. Peptide synthesis
4.3.1. Solid phase peptide synthesis (SPPS)
All peptide derivatives were synthesised on a scale of
0.025 mmol using Fmoc SPPS. Protected amino acids (4.2 equiv)
were activated using 4 equiv of HBTU and 6 equiv of DIPEA. Each
coupled amino acid was deprotected using 20% piperidine in
DMF before addition of the next amino acid. The coupling efﬁ-
ciency of each amino acid was quantiﬁed by nihydrin test,50 with
the exception of proline which was tested using the chloranil
test.51 Couplings were repeated until a coupling efﬁciency of
>99% was achieved. Coupling of glucoronic acid to the C-terminus
of the peptide was achieved using the protocol described in the lit-
erature.47,52 Attachment of carbohydrate succinamic acid deriva-
tives to the N-terminus of the peptides was achieved by
overnight coupling. After completion of the sugar coupling, the car-
bohydrate protection groups were removed by treatment with 75%
of hydrazine hydrate in methanol twice (15 min and 30 min,
respectively). The completed peptides were cleaved from the resin
using a mixture containing 95% TFA, 2.5% water and 2.5% triisopro-
pyl silane.
4.3.2. Peptide puriﬁcation
All crude peptides were puriﬁed by preparative RP-HPLC using a
Vydac C18 column (22  250 mm) with a gradient of 10–50% sol-
vent B over 72 min at a ﬂow rate of 20 ml/min. The purity of the
collected fractions was checked by ES-MS and analytical RP-HPLC.
Pure fractions were combined, lyophilized, and stored at 20 C.504.4. In vitro experiments
4.4.1. Cell culture
Cells were grown in T75 ﬂasks containing Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) media supplemented with 10% FBS and
1% nonessential amino acids. The monolayers were incubated at
37 C with 95% humidity in a 5% CO2 atmosphere. The medium
was changed every other day. Cells were subcultured using 0.25%
trypsin–EDTA when 80% conﬂuency was reached. Passage numbers
38–43 were used in these experiments.
4.4.2. Caco-2 cell homogenate stability assay
The medium was removed from a ﬂask containing Caco-2 cells
at 80% conﬂuence. The cells were washed once with EDTA 0.02%
and three times with 25 mM HBSS/HEPES buffer and the cells were
detached from the ﬂask using a cell scraper. The resulting cell sus-
pension was lysed using two  10 sec pulses on a Sonics Vibracell
ultrasonic processor with 40% amplitude in 130 W mode. Cell deb-
ris was precipitated by centrifuging at 2000 rpm for 10 min at 4 C.
The protein content was measured using the Bio-Rad assay and the
ﬁnal protein concentration was adjusted to 0.5–0.8 mg/mL in
HBSS/HEPES buffer. Test compound solutions (200 lM) were pre-
pared in HBSS buffer containing 25 mM of HEPES buffer. Cell
homogenate (100 lL) was mixed with 100 lL of test compound
solution in 96-well plates and incubated at 37 C. At selected time
intervals (0, 5, 10, 15, 20, 30, 40, 60, 90 and 120 min), 10 lL of mix-
ture was taken and transferred to another 96-well plate, containing
a mixture of TFA (5 lL), water (75 lL) and DMSO (10 lL). Samples
were then analysed using LC–MS.
4.4.3. Caco-2 cell monolayer permeability assay
Caco-2 cells were cultured in semi-permeable polycarbonate
Transwell plates with the following characteristic: 6.5 mm inserts
diameter, and polycarbonate membrane pore size of 0.4 lm. The
cell suspension was adjusted to a concentration of 1  106 cells/
mL and 100 lL of the cell suspension was seeded into the inserts.
Both apical (0.1 mL) and basolateral (0.6 mL) chambers were ﬁlled
with cell culture medium containing DMEM with 10% FBS, 1% non-
essential amino acids and 1% penicillin/streptomycin (10,000 units
of penicillin sodium salt/mL and 10 mg streptomycin sulphate/mL
in 0.85% saline). The media in both chambers was changed every
other day. For formation of well-differentiated monolayers of suit-
able conﬂuence the cells were grown for 21–28 days in the plates.
Before the start of the experiment, the media was removed from
both chambers, washed three times with preheated 25 mM of
HBSS/HEPES (pH 7.4), then reﬁlled with the same buffer. After
equilibration for 30 min at 37 C, TEER values were measured with
a Millicell-ERS epithelial volt ohmmeter instrument (Millipore
Company) to evaluate the integrity of tight junctions. Values rang-
ing from 0.9 to 1.4 k O cm2 were deemed acceptable for use in the
experiment.
Solutions of test compounds (200 lM) were prepared in HBSS/
25 mM HEPES. The compound solutions (200 lL) were added to
the apical side of the monolayer and incubated at 37 C. At prede-
termined time points (30, 90, 120, and 150 min) samples (400 lL)
were taken from the basolateral chamber and replaced with fresh
HBSS/HEPES buffer. At the end of the experiment, a 50 lL of aliquot
was collected from apical chamber of each well. All samples were
analysed by LC–MS.
Radiolabelled mannitol and propranolol were used as negative
and positive controls respectively. The radioactivity of 14C-manni-
tol was quantiﬁed by liquid scintillation counting (Liquid Scintilla-
tion Systems, Beckman LS3801) after addition of scintillation
cocktail (Perkin–Elmer-Optiphase). The apparent permeability of
test compounds was calculated using the following equation:
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Vr is the volume of the receiver chamber (cm3); dC/dt is the steady
state rate of the change in the chemical concentration (M/s); A is the
surface area of the cell monolayer (cm2) and C0 is the initial concen-
tration in the donor chamber (M).
4.4.4. LC–MS analysis
Samples collected from stability and permeability assays were
analysed by LC–MS using gradient elution HPLC coupled to a mass
spectrometer operating in selective ion monitoring mode. A gradi-
ent of 100% solvent A2 to 100% solvent B2 over 5.3 min at a ﬂow
rate of 0.5 mL/min was used to elute the peptides. A Vydac C8 col-
umn (5 lm, 50  2 mm) or Phenomenex Luna C18 column (5 lm,
50  2 mm) was used for this analysis.
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3.3 Introduction to this publication 
 
This section was accepted in ‘’AAPS journal’’ as an original article. In this article, the 
metabolic stability of the glycosyl derivatives of LHRH has been evaluated in different tissue 
homogenates including human plasma, ray liver and kidney membrane homogenates. The 
metabolites produced by the digestive enzymes in kidney membrane enzymes were 
characterised. The antiproliferative effect of the glycosylated compounds in a number of 
prostate cancer cell lines including LNCaP, DU145 and PC3 cell were investigated. 
Moreover, the stimulatory effect of selected LHRH analogues on the secretion of LH and 
FSH hormones from cultured rat pituitary cells was evaluated. 
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Abstract. The enzymatic stability, antitumor activity, and gonadotropin stimulatory effects of glycosylated
luteinizing hormone-releasing hormone (LHRH) analogs were investigated in this study. Conjugation of
carbohydrate units, including lactose (Lac), glucose (GS), and galactose (Gal) to LHRH peptide
protected the peptide from proteolytic degradation and increased the peptides’ half-lives in human
plasma, rat kidney membrane enzymes, and liver homogenate markedly. Among all seven modiﬁed
analogs, compound 1 (Lac-[Q1][w6]LHRH) and compound 6 (GS4-[w6]LHRH) were stable in human
plasma during 4 h of experiment. The half-lives of compounds 1 and 6 improved signiﬁcantly in kidney
membrane enzymes (from 3 min for LHRH to 68 and 103 min, respectively). The major cleavage sites for
most of the glycosylated compounds were found to be at Trp3-Ser4 and Ser4-Tyr5 in compounds 1–5.
Compound 6 was hydrolyzed at Ser4-Tyr5 and the sugar conjugation site. The antiproliferative activity of
the glycopeptides was evaluated on LHRH receptor-positive prostate cancer cells. The glycosylated
LHRH derivatives had a signiﬁcant growth inhibitory effect on the LNCaP cells after a 48-h treatment. It
was demonstrated that compound 1 signiﬁcantly increased the release of luteinizing hormone (LH) at 5
and 10 nM concentrations and compound 5 (GS-[Q1]LHRH) stimulated the release of follicle-stimulating
hormone (FSH) at 5 nM concentration in dispersed rat pituitary cells (p<0.05). In our studies, compound
1-bearing lactose and D-Trp was the most stable and active and is a promising candidate for future
preclinical investigations in terms of in vitro biological activity and metabolic stability.
KEY WORDS: antiproliferative activity; carbohydrate conjugation; LH and FSH release; LHRH;
peptide.
INTRODUCTION
Luteinizing hormone-releasing hormone (LHRH) is a
hypothalamic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2) with a regulatory function in the repro-
ductive system. The secretion of this hormone from the
hypothalamus stimulates its cognate receptor in the pituitary
gland to produce gonadotropins including luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH). Subse-
quently, the release of gonadotropins regulates the secretion
of sex steroids in both males and females (1). A substantial
number of LHRH derivatives have been developed and are
administered parenterally for the treatment of various
hormone-dependent diseases such as breast cancer, prostate
cancer, endometriosis, infertility, and precocious puberty (2,
3). There is no oral analog of LHRH in the clinic due to its
poor pharmacokinetic proﬁles and low oral bioavailability.
The rapid clearance of peptides from the human body is one
of the main issues in the development of therapeutic
compounds. They have very low stability in digestive enzymes
in the physiological environments. Therefore, in order to
develop an orally active LHRH derivative, the stability of the
peptide should be improved. Several strategies have been
explored to reduce the enzymatic cleavage of peptide in
physiological media. Conjugation of peptides with carbohy-
drate moieties has been shown to be a useful approach in
improving stability and permeability of the modiﬁed analogs
through biological membranes (4–6). Furthermore, a number
of studies demonstrated that the efﬁcacy of the sugar-
modiﬁed peptides is preserved in different animal models
(7–9).
To develop a potent drug, it is necessary to fully
characterize the designed compounds for biological and
physicochemical properties at the early stage of the discovery
process. The promising drug candidate selected from prelim-
inary characterization should possess desirable characteristics
such as high potency, long half-life, and an appropriate
physicochemical proﬁle. Understanding the metabolic path-
way of the target peptide is an important factor in evaluating
the therapeutic potential of the peptide drug candidates (10).
The blood, liver, and kidney are the main compartments of
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enzymatic digestion of peptides resulting in a reduction in the
peptide’s half-life (11). It has been reported that LHRH is
metabolized by proteolytic enzymes within a short period
of time post administration (12). The main cleavage sites
of this peptide are Trp3-Ser4 and Tyr5-Gly6 amide bonds
(12, 13). Typically, substitution of Gly at position 6 with a
D-amino acid in LHRH increases its metabolic stability
and the binding afﬁnity to LHRH receptor (14, 15).
Triptorelin is one of the LHRH super agonists bearing D-Trp6
and it is more stable to enzymatic degradation. Triptorelin is
administered parenterally for the treatment of prostate cancer
and hormone- dependent diseases (16).
It has been shown that LHRH analogs do not only
suppress the pituitary-gonadal axis but also exert a direct
growth inhibitory effect on the tumor growth (17). LHRH
receptors are overexpressed in malignant tumors such as
prostate, breast, and ovarian cancers, and they can
mediate the antitumor activity of LHRH derivatives (18,
19). Various studies showed that LHRH analogs induce a
signiﬁcant decrease in the growth rate of the cancer cells,
e.g., prostate cancer cell lines such as LNCaP and DU145
(20–22). LNCaP cells are androgen-dependent and are
derived from a lymph node metastasis of prostatic
carcinoma with a high level of LHRH receptor expression
(20). PC3 and DU145 cells are androgen-independent and
are derived from bone and brain metastasis of prostate
cancer, respectively (20, 22). Medium-to-high afﬁnity
binding sites were also reported for LHRH agonists in
LHRH receptor-positive prostate cancer cells (23). The
agonists exhibited their antiproliferative effect in a dose-
and time-dependent manner (24). LHRH agonists and
antagonists were shown to reduce the enzymatic activity
of the plasminogen activator system in prostate cancer
cells leading to a decrease in the migration and invasive-
ness of cancer cells (25). The mechanism of their growth
inhibitory effects is through a different signaling transduc-
tion pathway from that in the pituitary cells (25, 26).
Treatment of cultured pituitary cells with LHRH ago-
nists has been shown to alter the secretion level of LH and
FSH from gonadotrophs. This occurs when the agonist
binds to the receptor and the hormone-receptor complex
is internalized (27, 28). The long-time exposure of LHRH
receptors to the high concentrations of LHRH agonists
resulted in receptor desensitization and the lower doses of
the agonists increased the number of LHRH receptors
followed by stimulation of LH release (29, 30).
In the present study, we designed LHRH derivatives by
replacement of Gly residue with D-Trp and attachment of a
glycosyl unit to either N-terminus or middle sequence of the
peptide. The enzymatic stability of the designed compounds
(1–6) was then evaluated in human plasma and rat tissue
homogenates. The metabolites produced by the digestive
activity of kidney membrane enzymes were characterized,
followed by the examination of the degradation proﬁle of
the analogs. The direct antiproliferative potency of
glycosylated LHRH analogs was examined in prostate
cancer cells including LNCaP, DU 145, and PC3. We also
investigated the stimulatory activity of the selected glyco-
sylated LHRH derivatives (compounds 1, 2, 5, and 6) at
low concentrations to release LH and FSH in the cultured
pituitary cells.
MATERIALS AND METHODS
General
High-performance liquid chromatography (HPLC) grade
acetonitrile (MeCN) was purchased from Labscan (Bangkok,
Thailand) and triﬂuoroacetic acid (TFA) was obtained from
Merck Biosciences (Kilsyth, VIC, Australia). Reversed-
phase HPLC (RP-HPLC) was performed using Shimadzu
Instrumentation (Kyoto, Japan) (LabSolutions software,
SIL-20AC HT auto-sampler, LC-20AB pump, SPD-M10A
detector, DGU-20A5 degasser). The analysis was achieved
using a linear 0–100 or 20–60% gradient of solvent B
(solvent A, 0.1% TFA in H2O; solvent B, 90%
ACN:H2O:0.1% TFA) for 30 min with a 1-mL/min ﬂow
rate and detection at 214 nm. The crude peptides were
then puriﬁed by preparative HPLC with a linear 20–45%
gradient of solvent B to ≥95% purity. Analytical separa-
tions were performed using a C8 column (Vydac
208TP5205; 5: m, 2.1×50 mm2, Columbia, MD, USA) or
a C18 column (Vydac 218TP5405; 5: m, 4.6×50 mm2,
Columbia, MD, USA). Electrospray ionization mass
spectrometry was performed on a Perkin-Elmer Sciex
API 3000 operating in positive ion mode. A Varian Cary
50 Bio UV–vis spectrophotometer was used for absor-
bance measurement.
LNCaP (androgen-sensitive prostate adenocarcinoma)
and DU145 (androgen-independent human carcinoma) hu-
man cell lines were used and were kindly provided by
Professor Judith Clements at the Translational Research
Institute, Queensland University of Technology. PC3 (steroid
hormone-independent prostate adenocarcinoma) cells were
kindly donated by Professor Rodney Minchin, School of
Biomedical Sciences, The University of Queensland;
Dulbecco ’s modiﬁed Eagle ’s medium (DMEM);
penicillin/streptomycin; fetal bovine serum (FBS); and
phosphate-buffered saline (PBS) were obtained from Life
Technologies Australia (Mulgrave, VIC, Australia). Tris
(hydroxymethyl) aminomethane hydrochloride (Tris–HCl)
was purchased from ICN Biomedical Inc. (OH, USA).
MgCl2·6H2O was obtained from Sigma-Aldrich (Castle
Hill, NSW, Australia).
Peptide Synthesis
All LHRH analogs were synthesized using Fmoc solid
phase peptide synthesis (SPPS) based on the previously
published methods (Fig. 1) (31).
In Vitro Metabolic Stability Assay
Human Plasma Stability Assay
The test was performed on fresh human plasma of
consenting and healthy volunteers (ethics approval number:
2006000950). Plasma was separated from red blood cells by a
15-min centrifugation at 1500×g and diluted to 80% by adding
1× PBS. The compound’s solution was prepared in PBS at
600 μM. Plasma (300 μL) was spiked with the peptide
solutions at 1:1 ratio (incubated at 37°C). During the time
course of the experiment (4 h), samples were collected and
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mixed with acetonitrile for quenching the reaction. Finally,
the protein mixture was centrifuged at 7400×g for 10 min and
the supernatant was separated from the mixture and analyzed
by RP-HPLC. A calibration curve of each compound was
plotted (peak area of serial dilutions versus the concentra-
tions) to calculate the concentration of the peptide in the
sample’s solutions.
Rat Tissue Preparation
Male Sprague–Dawley rats (180±20 g were obtained from
the Animal Resource Centre (ARC). All experimental proce-
dures were approved by The University of Queensland Animal
Ethics Committee (AEC#SCMB/005/11/ARC) and performed
according to NHMRC animal handling guidelines. Animals
were euthanized and their kidneys and livers were removed to
prepare tissue homogenates. The rat liver homogenate, S9
(containing both cytosolic and microsomal enzymes) was
prepared according to the previously published methods (32,
33). Brieﬂy, the fresh rat liver was weighed and washed with ice-
cold 0.9% sodium chloride solution. The tissue was cut into
small pieces followed by mixing with 3 mL of 20 mM Tris–HCl
buffer (pH 7.4), containing 0.25 M sucrose per 1 g of tissue. The
samples were then homogenized with the ice-cold buffer in a
Teﬂon homogenizer using 4–6 pestle strokes. The homogenate
was centrifuged at 3000×g for 15 min at 4°C and the supernatant
was decanted. The total protein count was determined using
Bradford assay and the protein concentration was adjusted to
2.5 mg/mL. The kidney membrane homogenate was prepared
according to the procedure described by Vergote et al. with
minor modiﬁcations (10). In brief, rat kidneys were washed with
ice-cold 0.9% sodium chloride and transferred into the Tris–HCl
buffer (2mM containing 10mMmannitol, pH 7.3). After cutting
into pieces, the tissue was homogenized by a Teﬂon homoge-
nizer followed by centrifugation of the homogenate suspended
in ice-cold 10 mM MgCl2·6H2O and 2 mM Tris–HCl buffer
(1500×g, 15 min at 5°C). The supernatant was removed and the
pellet was re-suspended in the ice-cold buffer and centrifuged at
15,000×g for 15min at 5°C. The supernatant was discarded again
and the pellet was re-suspended in the buffer and centrifuged at
2200×g for 15 min at 5°C. After discarding the supernatant, the
suspended pellet was again centrifuged at 15,000×g for 15 min at
5°C. The supernatant was decanted and the ﬁnal pellet was re-
suspended in the same Tris–HCl buffer mix. The total protein
content of the suspended pellet wasmeasured byBradford assay
and adjusted to 2.5 mg/mL.
Fig. 1. Chemical structure of the glycosylated LHRH analogs
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Incubation of the Peptide Analogs with Homogenates
The homogenates were added (100 μL) into each well of
the 96-well plates. Prior to the start of the experiment, the
homogenates were pre-warmed for 15 min at 37°C. LHRH
compounds were dissolved in PBS and added to the
homogenates to give a ﬁnal concentration of 100 μM. The
reaction was initiated by incubating the plates at 37°C and
shaking at 50 rpm (Thermo Scientiﬁc MaxQ 4000 Benchtop
shaker, USA). Samples of 50 μL were collected from each
well at pre-determined time intervals (0, 5, 10, 15, 20, 30, 40,
60, 90, 120, 180, and 240 min) and added to the 50 μL of 80%
acetonitrile containing 0.1% formic acid to stop the enzymatic
activity. Samples were ﬁnally centrifuged at 3000×g for
15 min; the supernatants were collected and analyzed using
HPLC on a C8 column.
Identification of Metabolites
The metabolites formed by the degradation of the
compounds in the kidney membrane homogenate and human
plasma were characterized using HPLC and ESI-mass
spectrometry. The peaks from the HPLC were collected and
the corresponding mass was identiﬁed using mass spectrom-
etry (PerkinElmer-Sciex API3000).
In Vitro Cell Proliferation Assay
LNCaP and DU145 cell lines were grown in 75 cm2
culture ﬂasks containing RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS) and 1% non-essential
amino acids in a humidiﬁed atmosphere of 5% CO2.
Dulbecco’s modiﬁed Eagle’s medium (DMEM) was used to
grow the PC3 cell line. The cell media were changed every
2 days.
The cell proliferation was evaluated by assessing the
mitochondrial reduction of MTT using the established
procedure (34). Tumor cells including LNCaP, DU145, and
PC3 were seeded at the density of 2.0×104 cells/well and
allowed to attach for 4 h. LHRH compounds were added to
the plates at different concentrations (10, 50, 100, and
200 μM) in triplicate. Cells were incubated for 48, 72, and
96 h at 37°C. Fresh compound solution was added to the cells
every other day. After the end of the treatment, 10 μL MTT
(5 mg/mL) was added to each well. Plates were incubated for
a further 4 h. The medium was aspirated and 200 μL acidiﬁed
isopropanol (0.1 N HCl) was added to the wells to dissolve
formazan crystals. The absorption of each well was measured
using a Spectramax 250 microplate reader at the wavelength
of 570 nm. The percentage of cell viability for each compound
was calculated by comparing the absorbance of PBS added
samples (as a negative control). Sodium dodecyl sulfate
(SDS) was used as a positive control. Each experiment was
repeated twice.
Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
Assay was performed with the approval from the
University of Queensland Ethics Committee (ethical approval
number: 2009000661). A blood sample (4 mL) was collected
from a healthy adult volunteer and diluted with an equal
volume of RPMI. Diluted cell suspension was layered over
4 mL Ficoll and centrifuged at 400×g for 30 min. The white
cell interface including mononuclear cells was aspirated and
washed three times with RPMI 1640. Cells were re-suspended
in 10% FBS:RPMI and seeded in a 96-well ﬂat bottom plate
(TPP) at the density of 1×106 cells/mL. Cells were then
activated by adding 10 μg/mL of phytohemagglutinin and
incubated at 37°C in a 5% CO2 atmosphere. After 1-h
incubation, 10 μL of LHRH derivative was added to each
well at 50 and 200 μM. An MTT assay was performed after
48-h incubation using the same method as described for the
cell proliferation assay.
LH and FSH Release Assays
Rat Pituitary Cell Preparation
Pituitary cell dispersion was performed as described
elsewhere with some modiﬁcations (35). Brieﬂy, anterior
pituitaries were removed immediately after euthanizing rats by
CO2 inhalation and rinsed with Hanks’ balanced salt solution
(HBSS) containing 25 mM N-2-hydroxyethylpiperazine-N-2-
ethane sulfonic acid (HEPES) buffer (pH 7.2). Tissues were
minced with a razor blade into small pieces. The buffer was
removed and replaced by a collagenase enzyme solution (1 mg/
mL dissolved in 1% bovine serum albumin (BSA)/HBSS). The
pituitary fragments were incubated with the enzyme for 1 h at
37°C to become dissociated. After a gentle trituration, cells were
passed through a cell strainer (Costar) to remove clumps and
centrifuged at 400×g for 10 min. The supernatant was decanted
and the cells were suspended in DMEM media supplemented
with 10% FBS (growth media). Afterwards, cells were plated in
96-well plates at the density of 30,000 cells/well and incubated
for 72 h at 37°C.
LH and FSH Measurement
Plated pituitary cells were spun down at 1200×g for
10 min. Before the addition of LHRH compounds, pituitary
cells were washed and replaced by challenging media
containing DMEM with 0.1% BSA. Plates were then
incubated with 10 μL test solutions at 37°C for 2 h.
Compounds were used at 1, 10, and 50 nM for the LH
release assay and at 0.5, 5, and 10 nM (concentrations
were chosen based on some preliminary experiments) for
the FSH release experiment. The level of LH and FSH
was quantiﬁed with the commercial ELISA kit (USCN
Life Science Inc., Wuhan, China) according to the
manufacturer’s instructions.
RESULTS
Designed LHRH Analogs
Peptide derivatives were synthesized and puriﬁed to 95–
99% purity according to previously published methods (6,
31). The pure peptides were used for the biological evalua-
tions. Figure 1 shows the chemical structure of the glycosyl-
ated LHRH analogs. In all compounds, the carbohydrate
units were attached to the N-terminus of the peptide via a
succinamic acid linker except for compound 6 in which the
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glucose unit was coupled to the serine residue at position 4
through O-glycosylation.
In Vitro Metabolic Stability of LHRH Derivatives
To assess the metabolic stability of LHRH derivatives in
human plasma, compounds were incubated with plasma for
4 h and the half-life of each LHRH derivative was calculated
after quantifying the collected samples using HPLC. The
results showed that compounds 1 (bearing Lac at N-terminus
and D-Trp6) and 6 (bearing GS4 and D-Trp6) were stable
during the time course of the experiment. A signiﬁcant
increase was also observed in the plasma half-lives of the
compounds 2–5 compared to the native peptide (from
t1/2=6 min to more than 120 min).
The enzymatic stability of the glycosylated conjugates of
LHRH was also studied in rat liver and kidney membrane
homogenates at pH 7.3 (Table I). The half-lives of com-
pounds 1 and 2 in liver homogenate were 117 and 42 min,
respectively, which were enhanced signiﬁcantly compared to
the parent peptide (t1/2=5 min). The metabolic stability of
compounds 1 and 2 was also improved between 7- and 22-fold
in kidney membrane homogenate. Compound 6 was stable in
liver homogenate for 4 h and showed the highest half-life in
kidney membrane homogenate (t1/2=103 min) compared to
the other derivatives. The shortest half-life in both homoge-
nates was obtained for those compounds that had glucose and
galactose units in the N-terminal of their structures (com-
pounds 3–5). It was demonstrated that the glycosylated
LHRH derivatives were more rapidly hydrolyzed in the
kidney membrane homogenates than the liver homogenates.
Among the tested LHRH derivatives, compound 1 and
compound 6 were the most stable analogs, whereas com-
pound 3 had the least metabolic stability in all three matrices.
Characterization of the Metabolites
The metabolites generated by the enzymatic digestion of
LHRH analogs were identiﬁed in kidney membrane and
human plasma stability experiments. No degraded products
were found in the samples incubated with plasma; however,
several metabolites were identiﬁed upon the incubation of the
analogs in the kidney membrane homogenate. All fragments
were eluted from HPLC earlier than the native peptide in the
chromatographic separation using a gradient solvent system.
The analysis of the fragments illustrated indicated that the
peptide bonds Trp3-Ser4 and Ser4-Tyr5 were the most
susceptible positions in compounds 1–5, which were cleaved
after 10- and 15-min incubation with the homogenate,
respectively. Moreover, the cleavage of the Tyr5-Gly6 bond
was detected in compounds 1–5. The lactose unit was cleaved
from the LHRH peptide in compound 1 after 40 min, while
the cleavage between the glucose residue and the peptide in
compounds 4 and 5 was observed after 20 min.
Compound 6 was stable in the kidney homogenate, and
no metabolites were detected in the samples until 180 min.
After 180 min, a metabolite was detected by the cleavage of
the glucose from the peptide. Another degradation site was
found for compound 6 after 240 min at Ser4-Tyr5.
In Vitro Antiproliferative Study
The growth inhibitory effect of glycosylated conjugates
of LHRH was investigated in three LHRH receptor-positive
prostate cancer cell lines (LNCaP, DU145, and PC3). Cells
were treated with the different doses of LHRH compounds
and their effects on cell growth were assessed during four
consecutive days. The cell growth in LNCaP cells decreased
between 35 and 53% after 48-h treatment with compounds 1–
6 (at 100 and 200 μM concentrations). Similar inhibitory
effects on cell growth were observed after the treatment of
LNCaP cells for 72 and 96 h (30 to 55% growth reduction)
(Fig. 2a, S1-A). It was shown that LHRH compounds induced
the same or even higher levels of growth inhibition in LNCaP
cells compared to triptorelin at 200 μM concentration. This
effect was in a concentration-dependent manner.
The growth rate of DU145 cells was not changed
signiﬁcantly when cells were treated with glycosylated LHRH
derivatives for 48 h. However, the cell growth was inhibited
evidently (40% reduction) after 72 h treatment of the cells
with the compounds at 50, 100, and 200 μM concentrations
(Fig. S1-B). Compounds 1, 2, 4, and 6 reduced the viability of
DU145 cells to less than 50% after a 4-day treatment
(Fig. 2b). Similar to the LNCaP cell line, the cell growth
inhibitory effect of the sugar-modiﬁed compounds was
concentration-dependent in DU145 cells.
No signiﬁcant change was observed in the growth of PC3
cells after 48 and 72 h of treatments (Fig. S1-C). However, the
Table I. Half-Lives of Glycosylated LHRH Derivatives in Human Plasma and Tissue Homogenates
Compound number Peptide derivatives
Half-life (min)
Rat liver homogenate Rat kidney membranes Human plasma
– [pGlu1]LHRH (native) 5 3 6
1 Lac-[Q1][w6] LHRH 117 68 Stablea
2 Lac-[Q1]LHRH 42 22 187
3 Gal-[Q1]LHRH 17 8 124
4 GS-[E1]LHRH 17 8 138
5 GS-[Q1]LHRH 22 8 146
6 GS4-[w6]LHRH Stablea 103 Stablea
All metabolic stability assays were performed in triplicate in two independent repetitions. The half-life values are reported as the mean of
repeated experiments
LHRH luteinizing hormone-releasing hormone, Lac lactose, Gal galactose, GS glucose
aCompounds were stable during the time course of the experiment (4 h)
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incubation of PC3 cells with LHRH derivatives elicited up to
37% growth inhibition after a 4-day incubation at 100 and
200 μM concentrations (Fig. 2c). All tested compounds
showed a superior inhibitory effect on the growth of LNCaP
and DU145 cell lines than PC3 cells. LNCaP cells were kept
for an additional 5 days without any treatment with com-
pounds. The cells resumed growth after 5 days and their
viability reached the level of the negative control wells.
Cell Toxicity Against Non-cancerous Peripheral Blood
Mononuclear Cells (PBMCs)
The toxicity of compounds 1–6 was evaluated in PBMCs
isolated from the whole blood. None of the compounds
showed any toxic effect on these cells at 50 and 200 μM
concentrations (Fig. 2d).
In vitro LH and FSH Release
The level of released LH and FSH was measured after 2-h
incubation of compounds 1, 2, 5, and 6 (lead compounds
selected based on our preliminary results) with the cultured
pituitary cells. Compound 1 at 10 nM concentration stimulated
the release of LH signiﬁcantly from 47 ng/mL in the negative
control samples to 117 ng/mL (Fig. 3). The concentration of
1 nM caused a 2-fold increase in LH release, although it was not
statistically signiﬁcant. However, a higher concentration of the
compound 1 (50 nM) did not affect the LH level. Compound 6
inhibited the LH release signiﬁcantly at 50 nM. Compounds 2
and 5 did not show signiﬁcant effects in altering the release of
LH at any concentration (Fig. 3). Compound 5 had a signiﬁcant
effect in increasing the secretion of FSH at 5 nM. The FSH level
was not signiﬁcantly altered when the cells were treated by
compounds 1 and 2 at any concentration.
DISCUSSION
The therapeutic beneﬁts of LHRH derivatives have been
proven in the treatment of hormone-dependent diseases (36,
37). However, all agonists and antagonists of LHRH are
characterized by poor pharmacokinetic properties when they
are orally administered. The development of orally active
Fig 2. Antiproliferative effects of glycosylated LHRH analogs in cancer cell lines. a LNCaP, b DU145, and c PC3. Cancer cells were treated
with LHRH compounds for 48, 72, and 96 h at 10, 50, 100, and 200 μM. In this ﬁgure, the growth inhibitory effect of compounds is shown after
96-h treatment at 100 and 200 μM. All other relevant graphs are presented in supplementary information. d In normal PBMCs, the growth
inhibitory effects of LHRH derivatives at 50 and 200 μM was determined following 48-h incubation with cells. Each column represents the
mean±SD of the data obtained from experiments performed in triplicate. Statistical analysis was performed using a one-way ANOVA followed
by the Dunnett’s post hoc test and compared to PBS group (*p<0.05, **p<0.01, ***p<0.01)
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peptide drugs has been one of the major goals in the
pharmaceutical industry. Enzymatic digestion is one of the
main limiting factors in the oral delivery of peptides leading
to poor absorption from the gastrointestinal tract into the
systemic circulation. Several approaches have been employed
to overcome these challenges. We applied the glycosylation
approach and amino acid substitution with D-isoform to
overcome the poor oral bioavailability of native LHRH
peptide. We previously reported the enhanced stability of
the LHRH glycosylated derivatives in the Caco-2 cell
homogenates (31). Caco-2 cells are derived from human
colon adenocarcinoma, and they express the typical enzymes
of intestinal cells such as peptidases in high levels. Therefore,
they are applied as a useful model for drug metabolism
studies (38). In addition to intestinal enzymes, the liver and
kidney are the two main organs responsible for metabolizing
hydrophilic peptides using different types of proteases. In this
study, the metabolic stability of the designed LHRH analogs
was evaluated in rat liver and kidney membrane homoge-
nates. The results indicated that the metabolic stability of all
glycosylated analogs improved signiﬁcantly in the liver
homogenate compared to the native peptide and the com-
pounds bearing glucose and lactose with D-Trp6 amino acid in
the sequence (compounds 1 and 6) were the most resistant
analogs against enzymatic digestion. The glycosylated LHRH
compounds were shown to be less stable against metabolizing
enzymes in the kidney compared to that of the liver. This was
in line with the previous studies showing that the kidney plays
an important role in the metabolism of LHRH derivatives
(39, 40). The native LHRH is degraded rapidly in blood and
has a short half-life of 3–4 min (36). We showed that
compounds 1 and 6 remained intact in the human plasma
during the 4-h incubation. The half-lives of compounds 2–5
increased 20- to 30-fold compared to the LHRH peptide.
Overall, it was found that the introduction of a D-amino acid
and a lactose unit to the structure of LHRH peptide had a
signiﬁcant impact in improving the metabolic stability of the
modiﬁed analogs. Furthermore, the attachment of a glucose
unit at position 4 in compound 6 was shown to be the most
effective approach in the current study to protect the peptide
against enzymatic degradation.
The production ofmajor metabolites of the compounds 1–6
was examined upon incubation in the kidney membrane
homogenate. Compound 6 with the glucose unit attached to the
middle of the sequence showed higher metabolic stability than
other derivatives. No hydrolyzed metabolites were formed until
180-min incubation with the homogenate. After 180 min, a
glucose-free fragment and after 240 min, a hexapeptide (Tyr5-D-
Trp6-Leu7-Arg8-Pro9-Gly10-NH2) was detected. It was found
that the kidney endopeptidases cleaved the peptide bond at
positions 3 and 4 in compounds 1–5. This caused the formation
of a hexapetide (Tyr5-Gly6 [or D-Trp6]-Leu7-Arg8-Pro9-Gly10-
NH2) and heptapeptide (Ser
4-Tyr5-Gly6 [or D-Trp6]-Leu7-Arg8-
Pro9-Gly10-NH2) in the homogenate. The Tyr
5-Gly6 bond was
also degraded in compounds bearing Gly at position 6
(compounds 2–5). This digestion pattern was reported for
LHRH, and its analogs in other studies in which the stability
of the peptide’s derivatives was examined in different tissue
homogenates and organs (41–43). It has been shown that
metalloendopeptidase EP24.15, EP24.11, and the angiotensin-
converting enzyme (ACE) are mainly responsible for digestion
of the LHRH peptide. The endopeptidase E24.15 cleaves the
peptide bonds at Tyr5-Gly6 and His2-Trp3 whereas ACE
degrades the bond at Try3-Ser4 (44–46). The cleavage of the
sugar entities was found to be processed in the later stage of the
proteolytic reaction. It was also observed that pyroglutamyl
residue (pGlu) was cleaved after the removal of the sugar
entities from the N-terminus of the peptides’ sequence. The
cleavage of pGlu from the amino terminus of the peptides is
instigated by the enzymatic activity of pyroglutamyl peptidase
distributed in different mammalian tissues (47).
In addition to the suppression of gonadal steroids, a
number of studies reported the direct antiproliferative activity
of LHRH analogs in different tumor cell lines (17, 48, 49).
However, the mechanism of the action of LHRH analogs on
tumor cells is mediated through a different signal transduc-
tion pathway from that in the anterior pituitary (20, 50). We
tested the growth inhibitory effect of the LHRH derivatives
in three prostate cancer cell lines including LNCaP, DU145,
and PC3. We found that all tested peptide analogs markedly
inhibited the growth of LNCaP and DU145 cells after 48- and
72-h treatment, respectively. There was no signiﬁcant differ-
ence between the antiproliferative effects of compound 6
bearing a sugar unit at position 6 and the other glycosylated
analogs in which the sugar entities were attached to the N-
terminus of the peptide. There are reports in the literature on
Fig. 3. Effect of glycosylated LHRH derivatives on the release of a LH and b FSH in rat pituitary cells. Statistical analysis was performed using
a one-way ANOVA followed by the Dunnett’s post hoc test. ##p<0.05, decrease in the LH level when compared to the PBS group (*p<0.05,
**p<0.01, increase in the LH level when compared to the PBS group)
Biological Properties of Glycosylated LHRH Analogs
59
the direct inhibitory activity of other LHRH analogs in these
two cancer cell lines (22). The tested peptide analogs in this
study showed no signiﬁcant effect on the growth of PC3 cells
during 72-h treatment. However, there was a 22–38%
decrease in the growth of these cells after 96-h incubation
with the glycosylated LHRH analogs. In comparison with
LNCaP and DU145 cells, the growth of PC3 cells was less
affected by the LHRH compounds. It has been reported that
LNCaP cells overexpress LHRH receptors with moderately
high- and low-afﬁnity binding sites for the ligand, whereas
PC3 cells have only low-afﬁnity binding sites for the ligands
(20). We also showed that the glycosylated LHRH derivatives
had no toxic effect on normal peripheral blood cells
suggesting the selective antitumor activity of the compounds.
The stimulatory effect of glycosylated LHRH derivatives
on LH and FSH release from dispersed pituitary cells was
also examined in this study. The level of LH released in
cultured rat pituitary cells was measured after the treatment
of the cells with compounds 1, 2, 5, and 6 at different
concentrations. The best stimulatory effect was observed for
compound 1 at 5 and 10 nM whereas compounds 2 and 5 did
not exert any signiﬁcant impact on the secretion of LH.
Compound 6 reduced the secretion of LH signiﬁcantly at high
concentration (50 nM) compared to the negative control.
There are evidences showing that LHRH analogs could have
different effects on the LH release. The higher concentrations
of LHRH receptor ligands can desensitize the pituitary cells
in a time- and dose-dependent manner (29, 51, 52). It was
found that compounds 1 and 6 have the potential to change
the LH release from the anterior pituitary cells. Among all
LHRH-glycosylated conjugates, it was demonstrated that
only compound 5 induced the release of FSH effectively,
although it did not stimulate the release of LH in the pituitary
cells. In previous studies, it has been explained that LHRH
ligands and androgens have a differential effect on the release
of LH and FSH. This has been shown to be due to the
independent control over LH and FSH secretion both in vitro
and in vivo (53, 54).
CONCLUSIONS
In conclusion, we showed that the conjugation of carbohy-
drate units to LHRH enhanced its metabolic stability and
protected the peptide from enzymatic digestion signiﬁcantly in
rat tissue homogenates and human plasma. Furthermore, the
modiﬁed peptides exhibited an inhibitory effect on the growth of
the prostate cancer cell, LNCaP, DU145 and to a lesser extent
on PC3 cells. Compound 1 (Lac[Q1][w6]LHRH) was able to
stimulate LH release from anterior pituitary cells at lower
concentrations, and compound 5 increased the secretion of FSH
in cultured pituitary cells. Overall, compound 1 was the most
promising candidate with the desired stimulatory effect on LH
secretion from pituitary, in vitro antitumor activity and improved
metabolic stability.
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Figure S1 : Antiproliferative effects of glycosylated LHRH analogues in A) LNCaP and B) DU145 
C) PC3 after 48,72 and 96h treatment with glycosylated LHRH analogue 
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ABSTRACT: Luteinising hormone-releasing hormone (LHRH) analogues have wide therapeutic applications in the treatment of prostate
cancers and endocrine disorders. The structure of LHRH was modified using a glycosylation strategy to increase the permeability of the
peptide across biological membranes. Lactose, galactose and glucose units were coupled to LHRH peptide, and the impact of glucose
transporters, GLUT2 and SGLT1, was investigated in the transport of the analogues. Results showed the contribution of both transporters
in the transport of all LHRH analogues. In the presence of glucose transporter inhibitors, reduction in the apparent permeability (Papp)
was greatest for compound 6, which contains a glucose unit in the middle of the sequence (Papp = 58.54 ± 4.72 cm/s decreased to
Papp = 1.6 ± 0.345 cm/s). The basolateral to apical flux of the glycosylated derivatives and the impact of two efflux pumps was also
examined in Caco-2 cell monolayers. The efflux ratios (ERs) of all LHRH analogues in Caco-2 cells were in the range of 0.06–0.2 except
for compound 4 (galactose modified, ER = 8.03). We demonstrated that the transport of the glycosylated peptides was facilitated through
glucose transporters. The proportion of glucose and lactose derivatives pumped out by efflux pumps did not affect the Papp values of the
analogues. C© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3217–3224, 2014
Keywords: LHRH; SGLT1; GLUT2; transport; Caco-2 cell; peptides; MRP2; P-glycoprotein; glycosylation; efflux pumps
INTRODUCTION
Luteinising hormone-releasing hormone (LHRH) is a neuropep-
tide produced by the hypothalamus that stimulates the ac-
tivation of LHRH receptors in the pituitary to release LH
and follicle-stimulating hormone. The secretion of these two
hormones results in controlling the production of sex steroid
hormones in both male and female reproductive systems.1
LHRH analogues are currently applied for treatments of var-
ious types of diseases including hormone-dependant cancers
(i.e., prostate, breast and ovarian cancers), infertility and pre-
cocious puberty.2,3 Because there is no oral derivative of this
hormone, developing an analogue with improved oral bioavail-
ability is highly desirable.
Oral administration is themost preferred and accepted route
by patients. However, the poor metabolic stability and low per-
meability of peptides across biological barriers are one of the
major challenges for the pharmaceutical industry in the de-
velopment of oral peptide therapeutics.4 Research in peptide
delivery has demonstrated that improving oral absorption of
peptides is achievable through different strategies such as cycli-
sation, lipidation and glycosylation.5,6 Among these, incorpora-
tion of carbohydrate residues into the structure of peptides has
proven to be effective in enhancing metabolic stability against
enzymatic degradation and penetration of peptides through
membrane barriers. Generally, conjugation of carbohydrate
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moieties and active components can assist the carrier-mediated
active transport across biological membranes. Glycosylation
can also modify the physicochemical properties, such as po-
larity, solubility and stability of the conjugated peptide.7 We
have previously shown that glycosylation of LHRH enhanced
both metabolic stability and membrane permeability of this
peptide.8 In the present study, we investigated the role of car-
bohydrate transporters in the transport of LHRH-glycosylated
analogues across human colorectal adenocarcinoma (Caco-2)
cell monolayers. This cell line has been extensively used in
pharmaceutical research, especially in intestinal drug absorp-
tion studies as a model for transport across the intestinal
mucosa.9 Generally, a carrier-mediated system is required for
the penetration of hydrophilic constructs through phospholipid
membranes.10 Hexoses including glucose, galactose and fruc-
tose are examples of hydrophilic components, which are not
able to pass through cell membranes by passive transport.
Active and facilitative transport systems are responsible for
their transfer through intestinal cell membranes.11 Two differ-
ent types of membrane protein families mediate the transport
of compounds containing carbohydrate entities in most mam-
malian cells.11 Facilitative glucose transporters (GLUT) are
Na+-independent transporters, which transport sugars across
the membrane according to their concentration gradient.11 The
other group known as Na+-dependent transporters (sodium–
glucose-linked transporter or SGLT) transport hexoses actively
through cell membranes against the sugar concentration gra-
dient by using the energy obtained from the electrochemical
sodium ion gradient.12 In intestinal cells, both SGLT1 and
GLUT5 are monosaccharide transporters mainly residing on
the apical side of the brush border, whereas GLUT2 is the dom-
inant isoform of the transporter located on the basolateral side
Moradi, Varamini, and Toth, JOURNAL OF PHARMACEUTICAL SCIENCES 103:3217–3224, 2014 3217
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of the enterocytes.12 GLUT2 is also transiently expressed on
the apical surface of enterocytes in response to high concentra-
tions of sugar in the lumen; hence, it provides a major path-
way for carbohydrate absorption.13 GLUT2 and SGLT1 trans-
porters show different affinities for D-glucose and D-galactose.
At low concentrations, glucose is transported against a concen-
tration gradient by SGLT1, whereas, at higher concentrations
of glucose, GLUT2 is mainly involved in the transport of this
hexose.11,14 These transporters are proposed as useful targets to
transport therapeutic peptides through biological membranes.
Drug efflux systems also affect oral absorption of drug
molecules. P-glycoproteins (P-gp) and multidrug resistance-
associated protein (MRP) are efflux pumps present in the in-
testinal epithelium. They belong to a superfamily of membrane
proteins known as ATP-binding cassette (ABC) proteins.15,16
P-gp is predominantly located at the apical domain of entero-
cytes and is encoded by multidrug resistance (MDR1) genes
in humans.4 Among the MRP family, MRP2 is found in the
apical membrane of enterocytes and accounts for secretion of
compounds into the lumen.17 Several studies have revealed
that peptides and glycosides are both appropriate substrates
for P-gp efflux pumps, which can contribute in their low oral
absorption.18–20
In the current study, we investigated the role of GLUT2 and
SGLT1 in the transport of glycosylated LHRHderivatives using
Caco-2 cell membranes. The efflux ratio (ER) and the impact of
ABC transporters located in Caco-2 cell membranes were also
examined.
MATERIALS AND METHODS
General
Trifluoroacetic acid (TFA), N,N-dimethylformamide (DMF), 2-
(1H-7-Azabenzotriazol-1-yl)–1,1,3,3-tetramethyl uronium hex-
afluorophosphate (HATU) and acetic acid were purchased
from Merck Biosciences (Kilsyth, Victoria, Australia). High-
performance liquid chromatography (HPLC) grade acetonitrile
(MeCN) was purchased from Labscan ((Bangkok, Thailand).
Fmoc-protected amino acids and Rink amide MBHA resin
(100–200 mesh, 0.4–0.8 mmol/g loading) were obtained from
Nova-Biochem (Melbourne, Victoria, Australia) or Mimotopes
(Clayton, Victoria, Australia). All media and supplements for
cell culture work were purchased from Life Technologies and
the human epithelial colorectal adenocarcinoma Caco-2 cell
line was obtained from the American Type Culture Collection
(Rockville, Maryland).
Analytical reverse-phase HPLC (RP-HPLC) was performed
using the Agilent 1100 series system equipped with an au-
tosampler, UV detector, and fraction collector with a 1 mL/min
flow rate and detection at 214 nm. Electrospray ionisation–
mass spectrometry (ESI–MS)was performed on a PerkinElmer-
Sciex API3000 instrument using Analyst 1.4 (Applied Biosys-
tems/MDS Sciex, Toronto, Canada) software. A flow of a 1:1
mixture of solvent A (0.1% acetic acid in water) and B (0.1%
acetic acid in acetonitrile/water 9:1) at a rate of 0.05 mL/min
was used as the mobile phase. Separation was achieved using
a Shimadzu system equipped with a CBM-20A controller, LC-
20AT pump, SIL-10A autosampler, SPD-20A UV/Vis detector
(230 nm) and a FRC-10A fraction collector on either an analyt-
ical C8 column (Vydac 208TP5205; 5 :m, 2.1 × 50 mm2) or a
C18 column (Vydac 218TP5405; 5 :m, 4.6 × 50 mm2).
Synthesis and Purification of LHRH Derivatives
The method for synthesis and purification of compounds 1–5
followed those previously published by our group.8,21 Briefly,
glycosyl units were first synthesised from the D isomer of glu-
cose, galactose and lactose in four steps followed by purifica-
tion using flash or dry column chromatography. Then, peptide
derivatives were synthesised using the standard Fmoc solid
phase peptide synthesis procedure on MBHA resin and 4.2 eq
N"-Fmoc amino acids activated with 4 eq. HATU and 6 eq.
DIPEA. For synthesis of compound 6, Fmoc glycosyl serine was
synthesised separately according to the protocol described in
the following section and then coupled to the elongating pep-
tide by an overnight reaction using a proportion of 1.5 eq. The
acetyl group of the glycosyl residues was de-protected on a solid
support using a solution of 75% (v/v) hydrazine hydrate in
DMF twice for 15 and 20 min, respectively. Cleavage of pep-
tide from the resin was accomplished using a cocktail of TFA,
triisopropylsilane and water (95:2.5:2.5). Crude products were
characterised by analytical HPLC on a C18 column and mass
spectrometry. Finally, they were purified by preparative HPLC
on a C18 column. Pure fractions were lyophilised and kept at
−20◦C for the tests.
4-1-1 Synthesis of N′-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-
Tetra-Oacetyl-D-Glucopyranosyl)-L-Serine
This compound was synthesised according to the protocol
published by Kihlberg et al.22 Briefly, glucosepentaacetate
(600 mg, 1.5 mmol) and Fmoc-L-Ser-OH (660 mg, 2 mmol)
were dissolved in CH2Cl2 (30 mL), and then BF3·Et2O complex
(2 mL) was added drop-wise under N2 atmosphere and stirred
overnight at room temperature. The reaction mixture was then
diluted with CH2Cl2 and the organic phase was extracted with
1% HCl (3 × 30 mL) and H2O (2 × 30 mL). The organic phase
was dried with MgSO4 and concentrated by rotary evapora-
tion. The crude product was purified by preparative HPLC on
a C8 column (10 m, 250 × 21.20 mm2; Phenomenex, Torrance,
California) running with a gradient of 30%–60% solvent B over
60 min (solvent A: 0.1% TFA in water; solvent B: 0.1% TFA in
90% acetonitrile/water) at a flow rate of 10 mL/min. The pure
fractions were subsequently combined and lyophilised to give a
white powdery substance, which was characterised using NMR
spectroscopy and ESI–MS (Fig. 1a; Supplementary Figs. S1 and
S2). Pure yield: 32%.
1H-NMR (300 MHz, CDCl3) * 1.90, 1.95, 1.98, 2.0 (4s, 3H,
Ac), 3.92–3.95 (dd, 1H, J = 4.08 and 6.48 Hz, H-$), 4.10–4.17
(2d, 1H each, J = 5.44 and 6.16 Hz, H-6,6′), 4.20–4.25 (m, 1H,
H-5, H-$), 4.35–4.39 (t, 1H, 7.2 Hz, Fmoc CHAr), 4.40 (m, 1H,
Fmoc OCH2), 4.42–4.47 (m, 1H, H-") 4.72–4.74 (d, 1H, J =
7.08 Hz, H-1), 5.08–5.15 (m, 2H, H-2.3), 5.36 (dd, 1H, J = 2 Hz
and 1.9 Hz, H-4), 6.32 (d,1H, J = 8.12 Hz, NH).
ESI–MS (M+H)+ calcd 658.2136, obsd 658.2140.
Cell Culture
Caco-2 cells (passage 28–39) were cultured in Dulbecco’s modi-
fied Eagle’s medium (Invitrogen, Carlsbad, California) contain-
ing 10% foetal bovine serum and 1% nonessential amino acids.
Cells were grown in 5% CO2 with 95% relative humidity at
37◦C. The media were changed every 3 days. Cells were sub-
cultured using 2 mL of trypsin–EDTA 0.05% after reaching
more than 80% confluence.
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Figure 1. (a) O-glycosylation of Fmoc–serine reaction using peracetylated glucose (yield = 32%). (b) Structure of O-linked glycosylated LHRH.
Hexose Transport Experiment
When Caco-2 cells reached more than 80% confluence, 1 × 106
cells/well were seeded in inserts of 12-transwell plates (Corning
Costar, Cambridge, Massachusetts). The plate media were
changed every other day and after 21–28 days; the integrity of
the cells was checked by measuring their trans-epithelial elec-
trical resistance (TEER) value. Cells exhibiting a TEER of 0.85–
1.3 K cm2 were chosen for the experiment. Initially, cells were
washed three times with pre-warmed Hanks’ balanced salt so-
lution (HBSS) containing 25 mM N-2-hydroxyethylpiperazine-
N-2-ethane sulfonic acid (HEPES) buffer (pH 7.2) and incu-
bated for 30 min at 37◦C. Afterwards, the buffer was removed
and the wells refilled with 50 :L of transporter inhibitors, ei-
ther phloretin or phlorizin, and incubated for 30 min at 37◦C.
According to the literature, a concentration of 100 :M of each
inhibitor in phosphate-buffered saline has been shown to pro-
vide the best inhibitory effect.23,24 Compounds 1–6 (50 :L) at fi-
nal concentrations of 200 :M inHEPES/HBSSwere then added
to each apical (A) chamber. At pre-determined time intervals
(30, 90, 120 and 150 min), 400 :L samples were collected from
the basolateral (B) chamber, whichwere refilled by adding fresh
buffer after each sampling. Amixture of phloretin and phlorizin
and (100 :M each) was also used to give an optimum inhibi-
tion. Radio-labelled mannitol [14C] and propranolol were used
as negative and positive controls, respectively. Finally, sam-
ples were quantified by liquid chromatography–mass spectrom-
etry (LC–MS). The radioactivity of the [14C]-D-mannitol sam-
ples was quantified by liquid scintillation counting (LS6500;
Beckman Coulter, Fullerton, California, USA). To determine
the reproducibility of the test, this experiment was repeated
twice separately and in triplicate for each sample.
Bidirectional Transport Experiment
Preparation of Caco-2 cells was performed as previously de-
scribed in an earlier section. After 30 min incubation of cells
with the transport buffer (HEPES/HBSS), the buffer from the
donor side (apical chamber in the A–B direction, absorptive or
basolateral in the B–A direction secretory) was removed and
replaced with 200 :M of compound solution (pH 7.4) without
inhibitors. During the time course of the experiment, the plates
were incubated at 37◦C and shaken at 50 rpm. Samples of
400 :L were collected from the acceptor chamber at pre-
determined time points over 150 min (30, 90, 120 and 150 min)
from the basolateral side or 80 :L from the apical side), and the
same volume of buffer was replaced after each sampling. Dur-
ing the time course of the experiment, the pH was kept at 7.4 to
avoid any possible influence of this factor on the permeability
across the cells. Collected samples were subsequently analysed
by LC–MS. The ER of the compounds was calculated according
to the equation shown in the analysis section.
Efflux Transporter Inhibition Study
For the inhibition study, verapamil was used as a specific in-
hibitor of P-gp transporter, whereas MK-571 was used as a
selective inhibitor to block MRP2. To give the maximum in-
hibitory effect, a concentration of 100 :M of verapamil and
50 :M of MK-571 was added to both chambers. Results of this
study were then compared with the bidirectional transport of
tested compounds in the absence of inhibitors.
Data Analysis
Results are expressed as mean (±SEM) values performed in
triplicate. The apparent permeability (Papp) of both tests (un-
der sink conditions) was calculated according to the following
equation:
Papp = dC/dt× Vr/A × C0
where dC/dt is the steady-state rate of the change in the chemi-
cal concentration (M/s),Vr is the volume of the receiver chamber
(cm3), A is the surface area of the cell monolayer (cm2) and C0
is the initial concentration in the donor chamber (M).
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Table 1. The Sequence of the Glycosylated LHRH Analogues
Compound
Number
Peptide
Derivative Sequence
Pure
Yield (%)
1 Native LHRH EHWSYGLRPG 76
2 Laca-
[Q1][w6]LHRH
(Lac-)QHWSYwLRPG 33
3 Laca-[E1]LHRH (Lac-)EHWSYGLRPG 39
4 Galb-[Q1]LHRH (Gal-)QHWSYGLRPG 47
5 Glcc-[Q1]LHRH (Glc-)QHWSYGLRPG 58
6 Glc4-[Q1][w6]
LHRH
EHW(Glc)SYwLRPG 26
aLactose.
bGalactose.
cGlucose.
Under non-sink conditions, the following equation25 was
used to calculate the Papp of the compounds:
CR(t) = [M/(VD + VR)]+ (CR,0 − [M/(VD + VR)])e−PappA(1/VD+1/VR)t
where CR,0 is the drug concentration in the receiver chamber
at time t; M is the total amount of drug in both chambers; VR
andVD are the volumes of receiver and donor chambers, respec-
tively;CR(t) is the drug concentration in the receiver chamber at
a previous time; f is the sample replacement dilution factor; A
is the surface area of the monolayer and t is the time interval.
The statistical significance of differences among the groups
was evaluated using one-way ANOVA and Dunnett’s post-hoc
test. The differences were considered significant when p < 0.01
and p < 0.001.
The ER was calculated using the following equation:
ER = Papp,BA/Papp,AB
where Papp,BA is the permeability value from basolateral to api-
cal side and Papp,AB is the permeability value from apical to
basolateral side.
RESULTS
Synthesis of Glycosylated LHRH Derivatives
The synthesis and purification of compounds 1–5 were per-
formed by previously published methods.8 The glycosyl units
(lactose, galactose and glucose) were attached to the N-
terminus of LHRH peptide via a succinamic acid linker to
achieve compounds 1–5 (Table 1). In compound 2, a glycine
residue was replaced by D-tryptophan. A glucose unit was at-
tached to a serine residue in the middle of the peptide sequence
through anO-glycosidic linkage to achieve compound 6 (Fig. 1b;
Supplementary Fig. S3).
Hexose Transport Assay
Phloretin, a GLUT2 inhibitor,26 and phlorizin, a specific and
competitive SGLT1 inhibitor,26,27 were used to study the con-
tribution of sugar transporters to permeation of glycosylated
LHRH compounds. Sink conditions were achieved for the lac-
tose derivative of LHRH. However, the experiment for the
transport of compounds 4 and 5was not maintained under sink
conditions because of the back diffusion of compounds from the
receiver chambers. Therefore, the permeability coefficient of
Figure 2. Changes in Papp of glycosylated LHRH derivatives in the
presence or absence of glucose transporter inhibitors. Both phloretin
and phlorizin significantly reduced the permeation rate of glycosyl
derivatives 2–6. The statistical analysis was performed using one-way
ANOVA followed by Dunnett’s post-hoc test. Each value represents
mean ± SEM (n = 3 from three independent experiments). **p < 0.01
and ***p < 0.001 analogues versus untreated samples.
these compounds was calculated based on non-sink conditions.
We found that the Papp of derivatives 2–6 dropped significantly
in the presence of phloretin and phlorizin. This confirmed that
both SGLT1 and GLUT2 transporters are involved in the trans-
port of these LHRH analogues (Figs. 2 and 3). The inhibition of
GLUT2 resulted in a sixfold to 10-fold decrease in the Papp of
compounds 2–6 compared with the negative control. The trans-
port of analogues 2–6 was significantly reduced in the presence
of phlorizin (twofold to fourfold) compared with the negative
control (Supplementary Table S1). Specifically, the transport of
compound 6 was the most affected.
The concurrent addition of both phloretin and phlorizin in-
hibitors to the cells also resulted in a meaningful reduction in
the transport of all glycosylated LHRH compounds through the
Caco-2 cell membranes.
Evaluation of the Integrity of Caco-2 Cell Monolayers
[14C]-D-mannitol (negative control) was also used to investi-
gate the monolayers’ integrity. The Papp value of the [14C]-D-
mannitol was obtained at 0.77 × 10−7 cm/s, indicating that the
monolayers’ integrity was acceptable for use. There was less
than 10% reduction in TEER values at 2, 16 and 24 h after
the experiments, as compared with the initial values, which
was not statistically significant (p > 0.05). This indicated that
the monolayers’ integrity was not affected by any LHRH ana-
logues. In the presence of phloretin and phlorizin, an initial 40%
decline in the TEER values was observed; however, the cohe-
sion of the monolayer was retrieved after 18 h (Supplementary
Fig. S4).
ER Measurement
To determine the ER of LHRH derivatives, the transport of the
compounds was measured in both the secretory (B–A) and the
absorptive direction (A–B) in Caco-2 cell monolayers (Table 2).
The native peptide 1 showed a high transport rate in the se-
cretory direction that resulted in an ER value of 8.75. Among
the glycosylated LHRH derivatives (2–5), the transport of ana-
logue 4 was significantly higher in the B–A direction (Papp =
87 × 10−7 cm/s) than in the A–B direction (Papp = 11 ×
10−7 cm/s). This resulted in a higher ER (8.03) than for the
other analogues. The lowest ER belonged to compound 5 (0.06),
which contained glucose in its sequence.
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Figure 3. The concentration of the compounds transported across Caco-2 cell monolayers over time: the amount of each LHRH derivative
transported over time is presented separately. Compounds (200 :M) were incubated with cells in the presence and absence of the inhibitors. Six
sequential samples were taken at different time points (0, 30, 60, 90, 120 and 150 min) and were analysed by LC–MS. Data are shown as the
mean ± SEM (n = 3).
Table 2. Apparent Permeability of Glycosylated LHRH Derivatives
in Absorptive (A–B) and Secretory (B–A) Direction Across Caco-2 Cell
Monolayers
Papp (A–B)a Papp (B–A)b
Compound ×10−7 (cm/s) Efflux Ratio (ER)
1 1.02 ± 3.34 8.93 ± 2.45 8.75
2 38.42 ± 3.55 5.47 ± 0.54 0.14
3 36.76 ± 6.65 8.70 ± 0.96 0.22
4 16.04 ± 2.46 86.8 ± 2.15 8.03
5 34.61 ± 3.25 1.67 ± 0.72 0.06
aThe apparent permeability from apical to basolateral direction
(absorptive).
bThe apparent permeability from basolateral to apical direction (secretory).
Data are shown as the mean ± SEM (n = 3).
Efflux Transporter Inhibition Experiment
The role of P-gp and MRP2 transporters in the efflux of LHRH
analogues was investigated by comparing the Papp (B–A) in the
presence and absence of verapamil andMK-571 (Fig. 4). The for-
mer is a selective inhibitor of P-gp and the latter blocks MRP2
transporters. The efflux of glycosylated LHRH derivatives was
not significantly altered by verapamil in Caco-2 cell monolay-
ers (p > 0.05). However, co-incubation with MK-571 exhibited
a significant decrease in Papp (B–A) of compound 2, 3 and 4 (p <
0.001). Compound 4 was affected the most by MK-571 showing
a Papp (B–A) value at 86.8 × 10−7 cm/s post-treatment as com-
pared with a Papp value at 7.2 × 10−7 cm/s in untreated cells.
No significant change was observed in Papp (B–A) of compound
5 in the presence of the inhibitors. Native peptide 1 showed an
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Figure 4. Effect of MK-571 and verapamil on the Papp (B–A) of the
glycosylated LHRH derivatives in Caco-2 cell monolayers. MK-571
caused a significant decrease in Papp from basolateral to apical (B–
A) of compounds 2–4 in which verapamil resulted in a drop in its Papp.
The statistical analysis was performed using one-way ANOVA analy-
sis followed by Dunnett’s post-hoc test. Each value represents mean
± SEM (n = 3, from two independent experiments). *p < 0.05 and
***p < 0.001 inhibitor-treated versus control samples.
Figure 5. Mean Papp values of compound 4 from apical to basolateral
(A–B) and basolateral to apical (B–A) direction in Caco-2 cell mono-
layers in the presence or absence of 50 :M of MK-571 (n = 3, two
independent experiments).
86% reduction in the Papp (B–A) after treatment with verapamil
(Supplementary Table S2).
The Papp (A–B) of compound 4 was measured when MRP2
was blocked by MK-571. This inhibition caused more than a
43% increase in the transport of compound 4 from apical to the
basolateral direction (Fig. 5).
DISCUSSION
Several transporters are involved in the transport of drug can-
didates across intestinal cells. We examined the impact of glu-
cose transporters and efflux systems on vectorial transport of
glycosyl derivatives of LHRH peptide. The efficacy of glycosy-
lation in improving the drug-like properties of peptides has
been confirmed in several studies. In a study carried out by
our group, oral administration of a glycosylated derivative of
endomorphine-1 produced significant pain relief in a rat model
of neuropathic pain.28 It was also reported that the glycosy-
lation of serine or threonine in enkephaline opioid peptide
not only increased the binding affinity of the compound to
opioid receptors but also enhanced anti-nociceptive potency.29
Glycosyl units are attached to the N-terminus of peptides
through a linker such as succinamic acid. They are also cou-
pled to the serine or threonine residues in the middle of the
sequence.22 In this study, sugar units were attached to the N-
terminus of the peptide derivatives 2–5. In compound 6, the
glycosyl unit was attached to the side chain hydroxyl group of
serine residue through a process known as O-linked glycosyla-
tion. This compound (6) was designed and synthesised to allow
comparison between the transport rates of LHRH analogues
with glycosyl units at different positions. In a comparison be-
tween the Papp of compounds 5 and 6, twice the transport rate
was observed for compound 6. As the only difference between
the structures of 5 and 6 was the position of glucose unit, it is
plausible that the higher permeability of 6might be because of
the conjugation of the sugar in the middle of the sequence.
There is a proper correlation between the permeability of
drugs in Caco-2 cells and the absorption process in intesti-
nal cells that results in a reliable prediction of intestinal drug
absorption.30,31 In our previous study, we observed a signifi-
cant increase in the transport of some of the glycosylated ana-
logues of LHRH across Caco-2 cells.8 Here, we reported the im-
pact of a carrier-mediated transport system,where glycosylated
LHRH analogues penetrated through the intestinal cells. Ac-
tively growing Caco-2 cell monolayers means they are differen-
tiated and have become polarised resulting in the formation of
distinguishable apical and basolateral domains on the surface
of the semipermeable membrane.32 This results in the expres-
sion of SGLT1 and GLUT2 transporters at the same position as
in human intestinal cells.33,34 A comparison study between the
localisation of SGLT1 in Caco-2 cell membranes and the human
jejunumshowed the same distribution pattern in bothmodels.35
SGLT1 transporters are located on the apical side of the brush
borders and are mostly responsible for the transport of hexoses
into cells. GLUT2 transporters are localised on the basolat-
eral and apical sides of epithelial cells and mediate the absorp-
tion of carbohydrates from the intestinal lumen into the blood
circulation.36,37 In Caco-2 cell monolayers, SGLT1 is predomi-
nantly situated on the apical side, whereas GLUT2 is mostly
found on the basolateral side of the monolayer.36 In the pres-
ence of carbohydrates, GLUT2 proteins are also distributed on
the apical side of the monolayer.36 We described that inhibition
of GLUT2 and SGLT1 transporters by phloretin and phlorizin,
respectively, caused a significant reduction in the Papp of com-
pounds 2−5. However, these data indicated that the transport
of the compounds was mostly facilitated through the GLUT2
transporter system. In the brush border membrane, the trans-
port of glucose by GLUT2 is three times greater than that of
SGLT1.38 This is in agreement with the results we obtained for
all sugar-modified analogues including compounds comprising
lactose and galactose in their structure.
We also reported the impact of efflux pump systems in
pumping back the glycosylated LHRH from the Caco-2 cells.
P-gp and MRP2 serve as ATP-dependent efflux pumps, which
are localised in the apical membranes of polarised cells and
play an important role in drug disposition. They are involved
in the extrusion of xenobiotics to the extracellular environ-
ment. These proteins are also functionally expressed in Caco-
2 cells.39,40 We observed that the permeability of analogues
2–5 was variably influenced by the efflux transport systems.
Galactose-conjugated LHRH (4) showed the highest efflux rate
compared with the other analogues. This explains why the per-
meation rate of this compound is lower than that of glucose- and
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lactose-coupled analogues. The native LHRH peptide is also an
appropriate substrate for efflux pumps. In Caco-2 cell studies,
the drug candidates with ER > 2 are considered as appropriate
substrates for efflux transporters.41–43 In this study, the ER of
all glycosylated compounds was less than one except for com-
pound 4 and the native peptide (ER > 2).
Several modulators are competitive inhibitors of P-gp and
MRP2 transporters. Among them, verapamil, which is com-
monly used for inhibition of P-gp and MK-571, has been proven
to be a selective inhibitor of MRP2.44,45 The ERs of glycosy-
lated compounds in the presence of MRP2 and P-gp inhibitors
indicated that the compounds were predominantly effluxed by
MRP2. Thus, in comparison to MRP2, the contribution of P-
gp was less significant. A more than 12-fold decrease in the
Papp (B–A) of compound 4 in the presence of MRP2 inhibitor
proved the role of this efflux transporter in extrusion of that
compound. Furthermore, the inhibition of MRP2 enhanced the
apical to basolateral transport of compound 4 to more than
43%; this finding was in line with a previous study performed
by Chen et al.46 In our study, the Papp (B–A) of flavonoid gluco-
sides was not altered by inhibition of P-gp, whereas the contri-
bution of MRP2 in the efflux of those compounds was confirmed
in their research.46 It has been demonstrated that MRP2 trans-
porter is involved in the efflux of other flavonoid glucosides like
quercetin.47
CONCLUSIONS
We found that the incorporation of glycoside moieties including
glucose and lactose into LHRH peptide enhanced the penetra-
tion of the modified analogues in Caco-2 cell monolayer. GLUT2
and SGLT1 transporters contributed to the transport of sugar-
modified LHRH derivatives across cells. The proportion of glu-
cose and lactose derivatives of LHRH pumped out of the cells
through MRP2 transporter did not affect the absorption rate of
the analogues significantly. These results indicated that lactose
and glucose sugarmoieties are promising absorption enhancers
for the transport of LHRHpeptide across biologicalmembranes.
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Additional figures: 
 
 
Figure S1: Electrospray ionization mass spectrometry (ESI-MS) and analytical HPLC 
spectra of GS-Fmoc Serine: The compound was characterized using mass spectrometry and 
analytical HPLC. The purification of the glycosylated serine was performed on Vydac C8 column (22 
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x 250 mm) at a flow rate of 20 mL/min with a 60 minute gradient of 30 to 70% solvent B (0.1% TFA 
in acetonitrile/water 9:1; solvent A: 0.1%TFA in water). The purity of the fractions was confirmed by 
analytical HPLC on a Vydac C8 column (4.6 x 250 mm, 5 µm) at a flow rate of 1 mL/min and a 
gradient of 0 to 100% B over 42 minutes. 
 
 
 
 
              Figure S2: A 400 MHz 1H NMR spectrum of Glucose-FMOC-Serine: 
compound was dissolved in CDCl3. 
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Figure S3: ESI-MS and analytical HPLC spectra of C6: Characterization of compound was done 
using mass spectrometry and analytical HPLC. The crude peptide was purified by preparative HPLC 
on Vydac C18 column (22 x 250 mm) at a flow rate of 20 mL/min with a 60 minute gradient of 30 to 
60% solvent B. The purity of the fractions was confirmed by analytical HPLC on a Vydac C8 column 
(4.6 x 250 mm, 5 µm) at a flow rate of 1 mL/min and a gradient of 0 to 100% B over 42 minutes. 
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Figure S4. Trans-epithelial electrical resistance (TEER) value of Caco-2 cell monolayers (A) effect of 
phloretin and phlorizin (B) and glycosylated derivatives of LHRH on the integrity of the monolayers. 
Fig S5. The concentration of the compounds transported across Caco-2 cell monolayers in 
basolateral to apical direction as a function of time. 
 
Additional table: 
 
Table S1: The apparent permeability values of LHRH analogues in Caco-2 cell monolayers 
 
Table S2: Basolateral to apical permeability of glycosylated LHRH analogues in the presence of 
verapamil (P-gp inhibitor) and MK571 (MRP2 inhibitor) separately. Data are presented as the 
mean ± SEM (n=3) 
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3 36.76±6.65 3.62±0.248 17.2±2.73 0.84±0.11 
4 17.04 ±2.46 3.35±0.12 6.9±2.67 1.00±0.365 
5      34.61±3.25 4.5±0.285 11.4±2.46 1.45±0.474 
6 58.54±4.72 5.3±2.4 13.7±3.04 1.6±0.345 
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Number 
P
app
 (×10
-7
,cm/s) 
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MK571 
C1 1.22±0.43 5.05±0.85 
C2 3.79±0.73 0.62±0.14 
C3 6.10±1.03 1.14±0.10 
C4 72.00±4.26 7.17±1.03 
       C5       1.89±0.81      1.21±0.56 
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5.1  Introduction to this publication 
This chapter was submitted to ‘’International Journal of Pharmaceutics’’ journal. In this manuscript, 
the pharmacokinetic parameters of lactose derivative of LHRH as a lead glycosylated analogue 
(based on in vitro studies) were evaluated following oral administration to rats. The stimulatory 
effect of this compound on the secretion of LH was also investigated in vivo.  
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Abstract: 
 
In the current study, the efficacy and pharmacokinetic profile of lactose-conjugated luteinizing 
hormone releasing hormone (LHRH) was examined following oral administration in male rats. A 
rapid and sensitive liquid chromatography/mass spectrometry technique was developed and applied 
for measuring the concentration of lactose[Q
1
][w
6
]LHRH (compound 1) in rat plasma in order to 
allow measurement of pharmacokinetic parameters. LH release was evaluated using a sandwich 
ELISA. Maximum serum concentration (Cmax= 0.11 µg/ml) was reached at 2 h (Tmax) following oral 
administration of the compound at 10 mg/kg. The half-life was determined to be 2.6 h. The absolute 
bioavailability of the orally administered compound was found to be 14%, which was a remarkable 
improvement compared to zero-to-low oral bioavailability of the native peptide. Compound 1 was 
effective in stimulating LH release at 20 mg/kg after oral administration. The method was validated 
at a linear range of 0.01–20.0 µg/ml and a correlation coefficient of r2 ≥0.999. The accuracy and 
precision values showed the reliability and reproducibility of the method for evaluation of the 
pharmacokinetic parameters. These findings showed that the lactose derivative of LHRH has a 
therapeutic potential to be further developed as an orally active therapeutics for the treatment of 
hormone-dependent diseases. 
 
 
Keywords: LHRH, LC/MS, LH release, bioavailability, pharmacokinetic 
 
 
1. Introduction 
 
LHRH is a neuroendocrine decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) 
secreted by hypothalamus in a pulsatile manner, which stimulates its cognate receptor in the 
pituitary gland to release gonadotropins including luteinising hormone (LH) and follicle-stimulating 
hormone (FSH). Subsequently, the production of gonadotropins regulates the secretion of sex 
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hormones in both males and females (Clayton and Catt, 1981). Due to the biological importance, 
various LHRH analogues have been designed and developed after LHRH was sequenced in 1971 
(Matsuo et al., 1971; Schally et al., 1971). LHRH analogues are used clinically for the treatment of 
various hormone dependent diseases including prostate and breast cancers, endometriosis, fertility 
disorders and precocious puberty (Huirne and Lambalk, 2001). The continuous administration of 
LHRH or its agonists leads to an initial surge in the release LH, FSH and sex hormones 
subsequently, followed by down-regulation of the LHRH receptors and suppression of 
gonadotropin secretion (Millar et al., 2004).  
Endogenous LHRH has a short half-life of 4-8 min in human plasma (Barron et al., 1982; 
Redding et al., 1973). It is also rapidly degraded by organs including liver, kidneys, anterior 
pituitary, posterior pituitary, and hypothalamus (Müller et al., 1997). Due to poor stability, LHRH is 
not able to provide a long-term stimulation of the pituitary gland and exert a strong and long-acting 
agonist effect. Replacement with D-amino acids at cleavage sites of native peptides improves their 
stability against enzymatic digestion and thereby prolongs the biological half-life. Substitution of 
Gly
6 
with D-amino acid in endogenous LHRH enhances the enzymatic resistance and also receptor 
binding affinity of the peptide, which leads to a better agonist activity (Coy et al., 1976; Schally 
AV, 2003). Triptorelin is a synthetic super agonist of LHRH containing D-Trp at position 6 with a 
longer half-life (19 min) than the native peptide (Barron et al., 1982) and is parenterally 
administered for prostate cancer treatment (Heyns, 2005). 
Although LHRH agonists have shown improved metabolic stability compared to the native 
peptide, they are still not orally effective. Poor membrane permeability and susceptibility to 
digestion by gastrointestinal enzymes give rise to a low oral bioavailability of LHRH agonists (less 
than 1%) (Iqbal et al., 2012). These analogues are distributed into the extracellular space and 
metabolized by digestive enzymes and kidney. It is believed that LHRH analogues are 
predominantly cleared by the kidney due to rapid and extensive renal uptake following IV 
administration (Handelsman and Swerdloff, 1986). All commercial analogues of LHRH are 
administered through parenteral routes including subcutaneous and intramuscular (Beyer et al., 
2011; Padula, 2005). As the oral route is the preferred route of administration by patients, 
development of an oral delivery system for therapeutic peptides like LHRH is highly desirable. 
Manipulation of peptide structures using glycosylation strategy is known to be an effective 
approach to improve the metabolic stability and membrane permeability of modified analogues 
(Christie et al., 2014; Moradi et al., 2014; Powell et al., 1993). Glycosylation has been shown to 
improve the efficacy of some peptides in vitro and in vivo (Egleton et al., 2000; Wu et al., 2006; 
Yamamoto et al., 2009).  
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Liquid chromatography/mass spectrometry (LC/MS) is a highly selective automated tool for 
quantitative sample analysis (Niessen, 2003). In addition to high sensitivity and selectivity, LC/MS 
has the advantage of providing data that are easy to interpret compared to other applicable 
techniques (Gillespie and Winger, 2011). Immunoassays are other routine techniques used for 
screening and quantification of peptides. However, these assays have some drawbacks such as 
higher incidence of false positive results and the requirement for specific antibodies. Therefore, 
developing an LC/MS-based method can provide highly accurate and reliable peptide quantification 
in biological samples (Sofianos et al., 2008).  
In our previous study, we showed that conjugation of glycosyl units to LHRH peptide 
enhanced the in vitro stability and permeability of the modified peptides across Caco-2 cell 
monolayers (as an intestinal model). Among all glycosylated analogues, lactose conjugated LHRH 
demonstrated the best in vitro stability and membrane permeability (Moradi et al., 2013). In the 
current study, we measured the bioavailability and pharmacokinetic parameters of the lactose-
modified LHRH as the lead compound in rats. An LC/MS-based method was developed for 
quantitative sample analysis followed by compound extraction from serum using an optimized 
method of extraction. The stimulatory effect of the orally administered compound on LH release in 
rats was also examined over 24 hours. 
 
2. Experimental 
2.1 Materials and apparatus  
Lactose[Q
1
][w
6
]LHRH (compound 1) and lactose[Q
1
]LHRH were synthesized according to the 
published methods (Moradi et al., 2013). Lactose[Q
1
]LHRH was used as the internal standard (IS). 
HPLC-grade acetonitrile (MeCN) was purchased from RCI Labscan Ltd. (Bangkok, Thailand). 
Methanol (MeOH) in HPLC grade was purchased from Merck biosciences (VIC, Australia) and 
Formic acid (analytical grade, 99%) from Univar, Australia. Phosphate buffer saline (PBS) was 
purchased from Invitrogen Life Technologies. 
 
2.2 Animals 
Male Sprague Dawley rats weighing between 140–170 g were purchased from UQ Animal 
Resource Centre (ARC) and were kept for one week acclimatization period prior to initiation of 
experimental procedures. Rats were housed in groups of two or three with ad libitum access to food 
and water, in a room with controlled temperature (22.2 ± 0.2 
◦
C) and humidity (51–65%) on a photo 
period of 12 h light/12 h dark. For experiments, rats were divided into 3 groups of 5 animals; 
negative control, intravenously (IV) and orally (PO) dosed groups. All experimental procedures 
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were approved by The University of Queensland Animal Ethics Committee 
(AEC#SCMB/005/11/ARC). 
 
2.3 Sample preparation  
The rat plasma samples were thawed at room temperature and spiked with 100 µl of IS solution (to 
a final concentration of 1 µg/ml). Analytes were extracted from plasma using a liquid-liquid 
extraction method. Different concentrations of acidified MeCN (95%, 80% and 60%) and MeOH 
(95%, 80% and 60%) with 0.1% formic acid were used to optimize the analyte extraction method. 
Plasma proteins were precipitated by the addition of 500 µl extraction solutions and were then 
vortexed and centrifuged at 14000 × g, 15 min. The supernatant was collected and evaporated under 
a slow stream of nitrogen gas using a five-valve glass manifold. Extracted samples were 
reconstituted in 40 µl of water-acetonitrile-formic acid (90:10:0.1) and injected into the LC/MS 
system for analysis.  
 
2.4 Preparation of calibration standards and quality control samples 
Stock solutions of compound 1 (100 µg/ml) and IS (10 µg/ml) were prepared in water: acetonitrile 
90:10 containing 0.1% formic acid. Serial dilutions of the compound (60-0.2 µg/ml) were then 
prepared from the stock solution to be used as calibration samples. Calibration standards were 
freshly prepared by spiking dilutions into blank rat plasma to yield final plasma concentrations 
ranging from 0.05 to 30.0 µg/ml of compound 1 and 1µg/ml of IS solution. Quality control (QC) 
samples at the lower limit of quantification (LLOQ), low, middle and high concentrations (0.01, 2, 
10 and 20 µg/ml) were made daily from separately prepared stock solutions. The selected dilutions 
were added to 100 µL of plasma spiked with 20 µl of IS solution at a final concentration of 1 
µg/ml). Similar extraction method was then used for the preparation of QC samples. Calibration 
curves were plotted as the peak area ratio (Compound 1:IS) vs concentration. 
 
2.5 LC–MS analysis and quantification 
LC/MS was carried out on a Shimadzu HPLC (LC-10AT) system coupled to a PE Sciex (AB Sciex) 
API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Concord, Ontario, Canada). 
The instrument was operated in positive ion mode under the following conditions: Ion-Spray 
voltage, 5000 V; source temperature, 550 °C; curtain gas (nitrogen) at 8; collision gas (nitrogen) at 
5; declustring potential at 50; focusing potential at 220 and entrance potential at 10. 
Chromatographic separation was performed on a Phenomenex luna C18 column (5 μm, 
50 mm × 2.0 mm) with a gradient mobile phase of solvent A (0.01% acetic acid in water) and 
solvent B (90% acetonitrile, 10% water and 0.01% acetic acid). The compound was eluted with a 
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20-35% solvent B over 5 min at a flow rate of 0.5 ml/min. Total injection volume was 15 µL. The 
extracted ion chromatogram with m/z 877.1 at 3.3–3.4 min and m/z 812.2 at 3.9–4.1 min was 
detected for compound 1 and IS, respectively. 
 
2.6 Method validation  
The accuracy and precision, calibration curve performance and recovery of the method were 
evaluated. The calibration curve was plotted in the range of 0.05-20 µg/ml using 1/x weighting 
regression model. Calibration curves were evaluated using three separately prepared batches. For 
testing the accuracy and precision of the method, intra- and inter-day assays were performed for all 
QC samples. The intra-day assay was performed within one day by analysing triplicate of each 
concentration of QC samples. The inter-day assay was carried out on four separate days for QC 
samples (each concentration in triplicate) and repeated twice (in two separate weeks). The recovery 
efficiency of the extraction procedure was performed at three concentrations of compound 1 (0.01, 
10, and 20.0 µg/ml) and IS (1 µg/ml) from rat plasma. 
 
2.7 In vivo pharmacokinetic study 
Rats were administered compound 1 at 2.5 mg/kg IV, 10 and 20 mg/kg PO. About 300 µL of blood 
sample was collected from each rat by tail bleed prior to the start of the experiment and at selected 
time points (0.5, 1, 2, 4, 6, 8, 12 and 24 h). Samples were allowed to clot for 2 h at room 
temperature, followed by centrifugation at 1000×g for 20 min. Serum aliquots were stored at −80◦C. 
 
2.8 LH release assay 
Serum concentration of LH was measured by a sandwich ELISA, strictly adhering to methodology 
as published previously (Steyn et al., 2013). Briefly, a 96-well high-affinity binding microplate was 
coated with monoclonal antibody (anti-bovine LH beta subunit) and incubated overnight at 4°C. A 
standard curve was generated using a 2-fold serial dilution of mouse LH in 0.2% (w/v) BSA-
1×PBS-T (PBS with 0.05% Tween 20). The LH standards and plasma samples were incubated with 
50 µL of detection antibody (polyclonal antibody, rabbit LH antiserum) for 1.5 h followed by the 
addition of 50 µL horseradish peroxidase-conjugated antibody (polyclonal goat anti-rabbit 
antibody) and 1.5 h incubation at room temperature. O-phenylenediamine, substrate containing 
0.1% H2O2 was added to each well and left at RT for 30 minutes. The reaction was stopped using 3 
M Hydrochloric acid. The absorbance of each well was read at a wavelength of 490 nm (Sunrise; 
Tecan Group). The concentration of LH in whole blood samples was determined by interpolating 
the OD values of unknowns against a nonlinear regression of the LH standard curve. LH secretory 
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responses were expressed as the area under the curve (AUC) after normalizing data to the baseline 
value. The within and between assay coefficient of variation of LH assays were below 5%.  
 
2.9 Data analysis and statistical evaluation 
The pharmacokinetic profiles, including area under the plasma concentration vs. time curve (AUC), 
half-life (t1/2) and clearance (Cl) of each rat were analyzed by non-compartmental analysis (Phoenix 
WinNonlin 1.2; Certara Inc., Princeton, NJ, USA). The maximum plasma concentration (Cmax) and 
the time the Cmax is reached (Tmax) were directly computed from the plasma concentration vs. time 
graph. The oral bioavailability (F%) was calculated by the following equation: 
 
𝑭% = 100 ×
𝐷𝑜𝑠𝑒 𝐼𝑉 × 𝐴𝑈𝐶 𝑃𝑂
𝐷𝑜𝑠𝑒 𝑃𝑂 × 𝐴𝑈𝐶 𝐼𝑉
 
 
All the data are expressed as mean ± standard deviation. Statistical analysis of pharmacokinetic 
parameters was calculated using ANOVA followed by the Dunnett’s post hoc test. 
 
 
3. Results  
3.1 Method validation and quantification of compound 1 in rat plasma 
The chemical structures of compound 1 and compound 2 (IS) are shown in Fig. 1. 
Lactose[Q
1
]LHRH was used as IS due to the structural similarity to compound 1. The extraction of 
compound from rat plasma was performed using different concentrations of acidified MeOH and 
MeCN solutions. Among all extraction solutions tested, the best recovery of compound 1 and IS 
from rat plasma was obtained using 95% of MeCN in water. The recovery (%) was found to be 
above 80% for 0.05, 2 and 10 µg/ml of compound 1 (83.7%, 89.8%, and 91.3%, respectively).  
The calibration curve showed an acceptable linearity at r
2
=0.999 for the range of 
concentration used, from 0.05 to 20 µg/ml (Fig. S1). The lower limit of quantification (LLOQ) was 
0.01 µg/ml. The reproducibility of the method was confirmed by intra- and inter-day assays which 
were determined by analysing the LLOQ (0.01 µg/ml), low QC (2 µg/ml, n=3), medium QC (10 
µg/ml, n=3) and high QC (20 µg/ml, n=3) on four separate runs. The inter-day precision did not 
exceed 12% for the four concentrations of QC samples and the intra-day precision of the assay was 
between 2% and 15%. The accuracy of intra- and inter-day assays ranged from 95% to 105% for the 
analyte and IS (Table S. I). 
The method selectivity was determined by analysing the plasma samples spiked with the 
highest concentration of compound 1 without IS. No signal was detected for IS showing that there 
was no interference of the IS signal with the compound’s peak. Analysis of four sources of blank 
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plasma prepared from different rats showed no signal for compound 1 and IS indicating that source 
of plasma did not affect the signals obtained from compound 1 and IS. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Chemical structures of (A) lactose [Q
1
][w
6
]LHRH (compound 1)  and (B) lactose 
[Q
1
]LHRH (Compound 2; IS) 
 
 
3.2 Pharmacokinetic studies  
Pharmacokinetic parameters were analysed by non-compartmental analysis. The results are 
summarised in Table I as mean±SD of measurements from five animals per group. Following IV 
and PO administrations, the plasma concentration of the compound at various time points (during 
24 h) was measured using the established LC/MS method (Fig. 2). The AUCs were obtained at 
1.27±0.76 µg/ml*h and 0.709±0.24 µg/ml*h for IV and PO doses, respectively. The mean volume 
of distribution (Vd) and clearance of compound 1 were found to be 36.49 ml/kg and 1.96±0.52 
ml/h/kg, respectively, after IV administration. The peak plasma concentration of the compound was 
achieved after 2 h (Cmax= 0.11±0.03 µg/ml). The half-life of compound 1 in plasma was 2.6 h after 
PO dose, which was a significant improvement compared to the short half-life of native LHRH as 
reported in literature (4 min) (Redding et al., 1973). The oral bioavailability of the compound was 
measured to be 14%. 
 
(A) 
(B)  
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 Figure 2: Plasma levels of compound 1 (mean ± SD, n=5) following 2.5 mg/kg IV bolus (A) and 
10 mg/kg oral gavage (B) in intact male rats measured by LC/MS. 
 
Table 1: Pharmacokinetic parameters of compound 1 in rats after administration at 2.5 mg/kg IV 
and 10 mg/kg PO. Data are presented as mean ± SD (n = 5). 
Parameters        Value (Mean+SD)      Value (Mean+SD) 
                                          IV                               PO 
Body weight (g)            171±25.08             164.4±18.40 
AUC0-∞ (µg/ml*h)       1.27±0.76               0.709±0.24 
T1/2 (h)                            2.9±0.63                2.6±0.84 
Cl (ml/h/kg)                 1.96±0.52                      - 
Vd (ml/kg)                     36.49                            - 
Cmax (µg/ml)                     -                            0.11±0.03 
Tmax  (h)                             -                            2 
F (%)                                 -                           14 
 
 T1/2: half-life; Cl: clearance; Vd: volume of distribution; Cmax: maximum concentration; Tmax: time 
to reach Cmax. 
 
3.3 Efficacy of compound 1 in the release of LH  
To determine the changes in LH level after oral administration of compound 1, the normalised area 
under curves (nAUC) of LH released was obtained over 24 h. A marked increase in the level of LH 
was observed after oral administration of 20 mg/kg of compound 1 compared to the control (PBS) 
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group (from nAUC=4.45± 1.028 ng/24h in control group to nAUC=11.33± 1.65 ng/24h). However, 
the oral dose of 10 mg/kg did not stimulate the release of LH significantly over 24 h (Fig. 3). 
 
 
 
Figure 3:  Changes in the plasma level of LH calculated from a nAUC over 24 h following oral 
administration of compound 1 at 10 and 20 mg/kg. Each column represents the Mean ± SD (n=5). 
Statistical analysis was performed using a one-way ANOVA followed by the Dunnett’s post hoc 
test and compared to PBS group (***, p<0.01). 
 
4. Discussion 
In the present study, the pharmacological properties of lactose-[Q
1
][w
6
]LHRH was evaluated after 
PO and IV administration to rats. Due to the poor oral bioavailability, all commercial derivatives of 
LHRH are administered parenterally which is inconvenient for patients. The main objective of this 
research was to improve the bioavailability of LHRH following oral administration. Modification of 
therapeutic peptides by substitution of D-isoform of amino acids is known to be the effective 
strategy to improve their pharmacological properties and metabolic stability (Seitz, 2000; Werle and 
Bernkop-Schnürch, 2006). Glycosylation is another useful approach to improve the metabolic 
stability of peptides in physiological environments and increase their biological activity (Simerska 
et al., 2009; Ueda et al., 2009). We applied D-amino acid substitution together with glycosylation 
strategy to address the associated challenges and enhance the bioavailability of LHRH peptide. In 
our preliminary in vitro studies, we showed that glycosylation significantly enhanced the metabolic 
stability (up to 4-fold) and apparent permeability (7 to 15-fold) of LHRH across intestinal cell 
membranes (Moradi et al., 2013; Moradi et al., 2014). Based on those results, we selected 
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compound 1 as the most promising LHRH glycosylated derivative for oral administration and 
investigated the pharmacological profile of this analogue followed by oral administration to rats.  
For pharmacokinetic evaluation of compound 1, an accurate analytical tool was required to 
determine the peptide’s plasma concentration. Therefore, an LC/MS method was developed and 
validated for quantitation purposes. LC/MS is an automated technique with broad applications in 
quantification of pharmaceutical compounds and their metabolites in biological matrices. The 
selectivity, sensitivity and cost effectiveness of MS based methods make them a preferred analytical 
technique in pharmaceutical industry (Lee, 2003). The developed method in this study was capable 
of detecting the compound over a range of 0.01 to 20 µg/ml with a detection limit of 0.01 µg/ml. 
The precision and accuracy of the method was assessed by performing intra- and inter-day assays 
The precision value obtained was below 12% for the four QC levels which was in acceptable limit 
based on FDA guidelines (the precision value should not exceed 15%) (Rower et al., 2010). The 
high accuracy (98.2% and 97.9% for intra-day and inter-day, respectively) was also obtained 
showing the reliability of the developed method. Consequently, the validation of the method 
showed good reproducibility, accuracy, precision and linearity for quantification of compound 1 in 
rat plasma.  
A quick and easy extraction protocol was performed for precipitation of plasma proteins 
using liquid-liquid extraction method. It yielded over 80% recovery for three selected concentration 
of the compound. The high and consistent extraction recovery showed a negligible loss of the 
analyte during the sample preparation process, and did not vary from sample to sample. 
A significant improvement in the bioavailability (14%) and half-life of compound 1 (2.6 h) 
was observed after oral administration of compound 1 compared to the endogenous peptide (Iqbal et 
al., 2012; Redding et al., 1973). The increased half-life of the compound may account for the 
enhancement of its bioavailability. These findings demonstrate that the attachment of lactose to 
LHRH analogue significantly improved the pharmacological properties of native LHRH. This is in 
agreement with other studies we previously published showing that the modification of opioid 
peptide endomorphin-1 by a lactose moiety resulted in significant analgesic activity of the peptide 
following oral administration to rats (Varamini et al., 2012). To the best of our knowledge, this is 
the first report of an orally administered LHRH analogue with a remarkable half-life and 
bioavailability.  
Acute administration of LHRH agonists stimulates the pituitary gland to release LH, 
whereas the chronic administration results in suppression of the pituitary-gonadal axis and blockade 
of LH secretion (Pinski et al., 1996). Following single-dose oral administration (acute 
administration) of compound 1 to rats, their plasma LH level increased significantly compared to 
the negative control group. This finding demonstrated that compound 1 was able to produce 
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stimulatory effect in vivo following acute administration. Taken together, we improved the oral 
bioavailability of LHRH by conjugation of a lactose moiety and D-Tyr
6
 substitution while 
maintaining the activity.  
 
5. Conclusions 
In the present study, we applied glycosylation strategy together with D-amino acid substitution to 
develop an orally active LHRH analogue. A sensitive and specific LC/MS quantification method 
was developed and validated to evaluate the pharmacological activity of lactose-[Q
1
][w
6
]LHRH in 
vivo. The method was reproducible and reliable to be used for quantitative analysis of the 
compound in rat plasma. We showed that the conjugation of lactose residue to LHRH peptide 
increased its half-life and oral bioavailability in rats significantly. The newly designed analogue 
could also stimulate LH secretion upon oral administration. The improved pharmacological 
properties of lactose-[Q
1
][w
6
]LHRH render this analogue a promising candidate towards the 
development of an orally available LHRH therapeutics. 
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Figure S1. A representative calibration curve for compound 1 quantification in rat plasma. Analyte 
concentration was in the range of 0.01-20 µg/mL and IS concentration was 1 µg/mL.  
 
Table S. I: Intra- and inter-day precision and accuracy values for the developed method 
Nominal 
concentration 
(µg/mL) 
                  Intra-day (n=8)                                 Inter-day (n=6) 
   Accuracy              Precision         Accuracy                Precision 
(mean±SD,%)           (CV,%)       (mean±SD,%)            (CV,%)                                           
QC1: 0.01 
 
QC2: 2 
 
QC3: 10 
 
QC4:20 
101.04± 0.58          2.40±1.70        101.11±0.67            1.15±0.16 
 
99.67±1.39             4.17±2.27        102.33±0.58             3.17±2.35 
103.47±1.98           10.74±3.51      103.89± 2.55            8.38±1.61 
 
104.75±2.16           14.75 ±5.15      95.56±1.18              12.17±1.26 
SD: standard deviation; CV: coefficient of variation 
 
 
Calibration curve C1.rdb (C1): "Linear" Regression ("1 / x" weighting): y = 2.59 x + 0.0674 (r = 0.9990)
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6.1 Conclusion  
LHRH analogues have extensive therapeutic applications for the treatment of hormone 
dependent diseases such as infertility, endometriosis, breast and prostate cancers. Due to the poor 
oral bioavailability, all LHRH derivatives have to be administered through parenteral routes. This 
study focused on developing an effective system to improve the pharmacological properties and 
oral bioavailability of LHRH peptide.  
Chemical modification of peptides using glycosylation has been proven to be an effective 
approach in oral peptide delivery. We successfully designed and synthesized a library of LHRH 
derivatives by conjugation of different sugar units including glucose, galactose or lactose to the N-
terminus (via succinamic acid linker) or to Ser
4
 of LHRH sequence (through O-glycosylation) using 
SPPS approach. In addition to carbohydrate modification, two derivatives were synthesised with D-
Trp at position six instead of the Gly residue. The substitution of D-amino acids to LHRH at 
position six leads to 10- to 200- fold increase in the potency and enhancement of the enzymatic 
stability of the peptide. We aimed to address the poor pharmacokinetic profiles of the native LHRH 
by combining these two approaches (D-amino acid substitution and glycosylation).  
The impact of glycosylation on the apparent permeability of LHRH across cell membrane was 
investigated in Caco-2 cell monolayer as a well-established in vitro model of intestinal epithelium. 
The apparent permeability of the compounds bearing glucose and lactose at the N-terminus was 
improved significantly by approximately 6-7 folds compared to the native LHRH. The highest 
permeability value was observed for the compound bearing glucose at Ser
4 
(15 folds increase 
compared to native LHRH) and the galactose modified derivatives exhibited the lowest 
permeability. The position and the type of glycosyl units were shown to be influential to the 
permeation of LHRH through Caco-2 cell monolayer. We showed that glucose and lactose units 
could serve as promising absorption enhancers for improving the penetration of LHRH through 
Caco-2 cell monolayer. Moreover, the conjugation of glucose to Ser
4
 residue had the best impact on 
increasing the penetration of LHRH across Caco-2 cell monolayer.  
The impact of certain glucose transporters including GLUT2 and SGLT1 on the transport of 
glycosylated LHRH derivatives across Caco-2 cell monolayer was also investigated. It was 
confirmed that both transporters were involved in facilitating the transport of glycosylated peptides 
across Caco-2 cell monolayer.   
The contribution of efflux transporters in the extrusion of glycosylated LHRH derivatives 
from Caco-2 cells was examined and reported in this thesis. Efflux transport systems are considered 
as formidable biological barriers to oral drug delivery. They reduce the drug absorption by pumping 
back the drugs into the extracellular spaces. It was found that the permeability of the glycosyl 
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conjugates of LHRH was not significantly affected by the efflux pumps except for the galactose 
modified compound. This analogue had the highest efflux ratio showing that it was a proper 
substrate for one or more efflux transport systems. The possible role of MRP2 and p-gp transporters 
(as highly expressed isoforms of efflux transporters in Caco-2 cell membrane) was also 
investigated. Our studies showed that MRP2 was mainly involved in the efflux of glycosylated 
LHRH analogues (particularly galactose modified compound) whereas, p-gp contributed to the 
extrusion of the native LHRH.  
Therapeutic peptides are susceptible to the proteolytic enzymes located in the gastrointestinal 
tract. These digestive enzymes degrade the peptides before they reach to the target sites. The 
glycosylation of LHRH appeared to confer an increase in the enzymatic stability of the peptide. The 
glycosylated LHRH derivatives exhibited enhanced half-lives in different tissue homogenates 
(Caco-2 cell, rat liver and kidney membrane homogenates) and human plasma. In addition to 
stability data obtained for LHRH derivatives, it was found that kidney had a significant metabolic 
effect in the hydrolysis of the glycosylated LHRH analogues compared to the other matrices tested 
here. Among all tested analogues, GS
4
-[w
6
]LHRH and Lac-[Q
1
][w
6
]LHRH were the most stable 
derivatives in all studied biological matrices.  
The efficacy of glycosyl conjugates of LHRH was also studied by evaluating the stimulatory 
effect of the compounds in the release of LH and FSH from pituitary gland in vitro. Among tested 
analogues, Lac-[Q
1
][w
6
]LHRH demonstrated the best stimulatory effect in the secretion of LH 
hormone from the rat pituitary cells. The analogue bearing glucose at Ser
4
 residue exhibited an 
inhibitory effect on LH release in the treated pituitary cells. Moreover, GS-[Q
1
]LHRH was capable 
of stimulating the release of FSH in dispersed rat pituitary cells. These findings provided useful 
insight into the stimulatory activity of the carbohydrate modified LHRH derivatives in the release of 
gonadotropins.   
The anti-proliferative activity of the glycosylated LHRH analogues was investigated in three 
LHRH-receptor positive cancer cells, PC-3, LNCaP and DU145. A meaningful reduction was 
observed in the viability of LNCaP and DU145 cells following treatments by glycosylated 
compounds in concentration-dependent manner. The treatment of PBMCs at the same 
concentrations did not show any growth inhibitory effect indicating that glycosylated LHRH 
analogues are non-toxic to normal cells like PBMCs.  
Based on the data obtain from in vitro studies, Lac-[Q
1
][w
6
]LHRH was chosen as the lead 
candidates for in vivo investigations. The oral bioavailability of this compound was improved 14-
fold which was remarkable compared to the poor bioavailability of native peptide. Moreover, a 
significant increase was observed in the half-life of this analogue following oral administration 
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which may account for the improved bioavailability of the lactose bearing LHRH analogue 
compared to the endogenous peptide. The in vivo efficacy of Lac-[Q
1
][w
6
]LHRH was also 
evaluated in rats at 20 mg/kg following oral administration. An increase was observed in the level 
of LH secreted into the blood compared to the control group (measured over 24 hours). According 
to these results, Lac-[Q
1
][w
6
]LHRH possessed promising pharmacological properties to be 
considered as an orally active analogue.  
Taken together, the promising results of these in vitro and in vivo studies demonstrated that 
the conjugation of carbohydrate units to LHRH had a pronounced effect in improving the 
pharmacokinetic profiles of the modified peptides. Moreover, the lactose and glucose bearing 
analogues exhibited direct antitumor activity in prostate cancer cells and stimulated LH release 
form pituitary gland. The pharmacokinetic advantages and maintained efficacy of the lactose and 
glucose derivatives of LHRH rendered these analogues promising candidates for the development 
of orally active LHRH pharmaceuticals. 
  
6.2 Future directions 
This thesis provided some useful information on the improved pharmacokinetic profiles of 
glycosyl conjugates of LHRH to be orally administered. The further investigations could help to 
improve the current knowledge concerning the designed system for oral delivery of LHRH peptide. 
In this project, we showed the efficacy of lactose and glucose modified LHRH analogues to 
stimulate the LH and FSH release from pituitary gland. Receptor binding affinity and understanding 
the mechanism of action of LHRH glycosyl conjugates would be the future in vitro studies that 
could give useful knowledge on the activity and specific binding of the glycosylated analogues to 
the cognate receptor.  
One of the major finding of this project was the improved pharmacological properties of Lac-
[Q
1
][w
6
]LHRH. Further investigation of whether the increase in the administered dose will enhance 
the bioavailability and efficacy of this compound would be desirable. Evaluating the long-term 
effect of this analogue on the suppression of LH production (four to seven weeks of consecutive 
treatment) through oral route would be also worth of study. Another important study is to 
investigate the biodistribution of this compound following oral administration to rats which will 
provide pivotal information on the accumulation of this analogue in different organs including 
kidney, liver, stomach and brain. As described in this thesis, Lac-[Q
1
][w
6
]LHRH exerted a 
significant anti-proliferative activity on prostate cancer cells. Further studies could be performed to 
assess the in vivo anti-tumour activity of this analogue in a prostate cancer model and evaluate its 
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long-term effect on the tumour size. Histological observation by monitoring the morphological 
changes in the prostate organ is clearly beneficial. 
Based on the in vitro data provided in this thesis, GS
4
-[w
6
]LHRH is another promising 
analogue with improved metabolic stability and membrane permeability to be further investigated 
for in vivo biological properties. The comparison studies between the pharmacological profiles of 
GS
4
-[w
6
]LHRH and Lac-[Q
1
][w
6
]LHRH will also offer informative data to find out the impact of 
the position and type of the glycosylation on biological properties of the glycosylated LHRH 
analogues. 
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